Autosomal Recessive Ataxia Due to Ubiquinone Deficiency

Neurological Disorder MONDO:0012784 Pathograph 22 Mendelian Disorder Neurological Disorder

Ask OpenScientist

Ask a research question about Autosomal Recessive Ataxia Due to Ubiquinone Deficiency. OpenScientist will conduct autonomous deep research using the Disorder Mechanisms Knowledge Base and PubMed literature (typically 10-30 minutes).

Submitting...

Do not include personal health information in your question. Questions and results are cached in your browser's local storage.

7
Pathophys.
11
Phenotypes
22
Pathograph
1
Genes
1
Treatments
1
Subtypes
2
Differentials
30
References
2
Deep Research
◆

Subtypes

1
COQ8A-ataxia
The best-characterized form of autosomal recessive ubiquinone-deficiency ataxia, also known as primary coenzyme Q10 deficiency-4, ARCA2, or SCAR9.
Show evidence (1 reference)
DOI:10.3390/metabo12100955 SUPPORT Human Clinical
"COQ8A-ataxia is a mitochondrial disease in which a defect in coenzyme Q10 synthesis leads to dysfunction of the respiratory chain."
This directly supports COQ8A-ataxia as the core mechanistic subtype within this MONDO disease concept.
⚙

Pathophysiology

7
COQ8A-Dependent Coenzyme Q10 Deficiency
Biallelic COQ8A dysfunction disrupts coenzyme Q10 homeostasis, producing a primary coenzyme Q10 deficiency state that underlies the disease.
COQ8A link
ubiquinone biosynthetic process link ↓ DECREASED
Downstream
Coenzyme Q10 level COQ8A deficiency lowers cellular CoQ10 content.
Impaired Oxidative Phosphorylation Reduced CoQ10 availability compromises mitochondrial energy transfer.
Show evidence (1 reference)
DOI:10.3390/metabo12100955 SUPPORT Human Clinical
"COQ8A-ataxia is a mitochondrial disease in which a defect in coenzyme Q10 synthesis leads to dysfunction of the respiratory chain."
This directly supports the upstream metabolic defect in CoQ10 biosynthesis caused by COQ8A deficiency.
Impaired Oxidative Phosphorylation
Reduced coenzyme Q10 availability impairs respiratory-chain function and mitochondrial energy production, creating a mitochondrial ataxia phenotype.
oxidative phosphorylation link ↓ DECREASED mitochondrial electron transport, NADH to ubiquinone link ↓ DECREASED
Downstream
Progressive Cerebellar Neurodegeneration Energy failure drives selective cerebellar vulnerability and progressive ataxia.
Oxidative Stress and Mitochondrial Homeostasis Defects ADCK3-deficient patient cells show oxidative stress and disordered mitochondrial homeostasis downstream of impaired CoQ10-dependent mitochondrial function.
COQ8A-Related Multisystem Brain Disease Respiratory-chain dysfunction in COQ8A disease manifests as a progressive multisystem neurologic syndrome rather than isolated cerebellar ataxia.
Systemic Mitochondrial Energy Limitation CoQ10-dependent respiratory-chain dysfunction can extend beyond the cerebellum and limit systemic exercise tolerance.
Serum lactate level Respiratory-chain dysfunction in COQ8A disease can be accompanied by elevated circulating lactate.
Show evidence (1 reference)
DOI:10.3390/metabo12100955 SUPPORT Human Clinical
"COQ8A-ataxia is a mitochondrial disease in which a defect in coenzyme Q10 synthesis leads to dysfunction of the respiratory chain."
The same abstract directly links CoQ10 deficiency to respiratory-chain dysfunction, supporting impaired oxidative phosphorylation.
Oxidative Stress and Mitochondrial Homeostasis Defects
ADCK3/COQ8A-deficient patient cells have oxidative stress, altered mitochondrial homeostasis, and lysosomal accumulation, providing a cellular stress pathway between CoQ10-dependent respiratory-chain dysfunction and neural vulnerability.
response to oxidative stress link ↑ INCREASED
Downstream
Progressive Cerebellar Neurodegeneration Oxidative and mitochondrial homeostasis stress provide a plausible cellular route to selective cerebellar injury in COQ8A disease.
Show evidence (1 reference)
PMID:26866375 SUPPORT In Vitro
"lines derived from ARCA-2 patients display signs of oxidative stress, defects in mitochondrial homeostasis and increases in lysosomal content."
Patient-derived cell studies support oxidative stress as a cellular consequence of ADCK3/COQ8A deficiency.
Systemic Mitochondrial Energy Limitation
CoQ10-dependent respiratory-chain dysfunction can impair energy production during exertion, producing exercise intolerance in a subset of patients.
oxidative phosphorylation link ↓ DECREASED
Downstream
Exercise Intolerance Systemic mitochondrial energy limitation manifests clinically as exercise intolerance.
Show evidence (1 reference)
DOI:10.1002/ana.25751 SUPPORT Human Clinical
"to exercise intolerance (25%)"
The multicenter cohort documents exercise intolerance as a recurrent non-cerebellar feature.
Progressive Cerebellar Neurodegeneration
COQ8A-related ubiquinone deficiency preferentially injures cerebellar systems, producing early-onset progressive cerebellar ataxia with universal cerebellar atrophy on MRI in the largest cohort.
Purkinje cell link
cerebellum link
Downstream
Ataxia Cerebellar system degeneration produces the core ataxic phenotype.
Cerebellar Atrophy Structural cerebellar volume loss is the imaging hallmark of disease.
Dysarthria Cerebellar system involvement can produce dysarthria in COQ8A disease.
Tremor Cerebellar system involvement can include head and intention tremor.
Show evidence (1 reference)
DOI:10.1002/ana.25751 SUPPORT Human Clinical
"COQ8A‐ataxia presented as variable multisystemic, early‐onset cerebellar ataxia,"
This supports cerebellar neurodegeneration as the dominant clinical and anatomical disease axis.
⬡

Pathograph

Use the checkboxes to hide or show graph categories. Hover nodes for evidence and cross-linked metadata.
Pathograph: causal mechanism network for Autosomal Recessive Ataxia Due to Ubiquinone Deficiency Interactive directed graph showing how pathophysiology mechanisms, phenotypes, genetic factors and variants, experimental models, environmental triggers, and treatments relate through causal and linked edges.
●

Phenotypes

11
Nervous System 9
Ataxia VERY_FREQUENT Progressive cerebellar ataxia (HP:0002073)
Course: PROGRESSIVE Onset: CHILDHOOD
Show evidence (1 reference)
DOI:10.1002/ana.25751 SUPPORT Human Clinical
"COQ8A‐ataxia presented as variable multisystemic, early‐onset cerebellar ataxia,"
Directly supports ataxia as the core and defining disease phenotype.
Dysarthria FREQUENT Dysarthria (HP:0001260)
Show evidence (2 references)
PMID:32743982 SUPPORT Human Clinical
"Neurological examination revealed mild dysarthria, overt head tremor, bilateral dysmetria, and intention tremor on nose‐finger and heel‐shin tests"
Clinical examination directly documents dysarthria in a patient with COQ8A disease.
PMID:31621627 SUPPORT Human Clinical
"clinical phenotype characterized by slowly progressive or static writing difficulties, focal dystonia, and speech disorder"
The clinical review supports speech disorder as a recurring feature in COQ8A mutation carriers.
Tremor FREQUENT Tremor (HP:0001337)
Show evidence (1 reference)
PMID:32743982 SUPPORT Human Clinical
"Neurological examination revealed mild dysarthria, overt head tremor, bilateral dysmetria, and intention tremor on nose‐finger and heel‐shin tests"
Clinical examination directly documents overt head tremor and intention tremor in COQ8A disease.
Cerebellar Atrophy VERY_FREQUENT Cerebellar atrophy (HP:0001272)
Show evidence (1 reference)
DOI:10.1002/ana.25751 SUPPORT Human Clinical
"Cerebellar atrophy was universal on MRI (100%),"
This directly supports cerebellar atrophy as a universal imaging phenotype in the cohort.
Seizure FREQUENT Seizure (HP:0001250)
Show evidence (1 reference)
DOI:10.1002/ana.25751 SUPPORT Human Clinical
"with complicating features ranging from epilepsy (32%) and cognitive impairment (49%)"
This supports seizure/epilepsy as a frequent complicating phenotype.
Cognitive Impairment FREQUENT Cognitive impairment (HP:0100543)
Show evidence (1 reference)
DOI:10.1002/ana.25751 SUPPORT Human Clinical
"with complicating features ranging from epilepsy (32%) and cognitive impairment (49%)"
This directly supports cognitive impairment as a common multisystem manifestation.
Developmental Regression FREQUENT Developmental regression (HP:0002376)
Onset: CHILDHOOD
Show evidence (1 reference)
DOI:10.3390/metabo12100955 SUPPORT Human Clinical
"The disease is usually present as childhood-onset progressive ataxia with developmental regression and cerebellar atrophy."
Review directly names developmental regression as part of the usual childhood-onset presentation.
Dystonia FREQUENT Dystonia (HP:0001332)
Show evidence (1 reference)
DOI:10.1002/ana.25751 SUPPORT Human Clinical
"hyperkinetic movement disorders (41%), including dystonia and myoclonus as presenting symptoms"
Directly names dystonia as a presenting symptom within the frequent hyperkinetic movement disorder group.
Myoclonus FREQUENT Myoclonus (HP:0001336)
Show evidence (1 reference)
DOI:10.1002/ana.25751 SUPPORT Human Clinical
"hyperkinetic movement disorders (41%), including dystonia and myoclonus as presenting symptoms"
Directly names myoclonus as a presenting symptom within the frequent hyperkinetic movement disorder group.
Constitutional 1
Exercise Intolerance OCCASIONAL Exercise intolerance (HP:0003546)
Show evidence (1 reference)
DOI:10.1002/ana.25751 SUPPORT Human Clinical
"with complicating features ranging from epilepsy (32%) and cognitive impairment (49%) to exercise intolerance (25%)"
This directly supports exercise intolerance as a recurrent non-cerebellar phenotype.
Other 1
Hyperkinetic Movement Disorder FREQUENT Hyperkinetic movements (HP:0002487)
Show evidence (1 reference)
DOI:10.1002/ana.25751 SUPPORT Human Clinical
"hyperkinetic movement disorders (41%), including dystonia and myoclonus as presenting symptoms"
This directly supports hyperkinetic movement disorders as a frequent phenotype in COQ8A-ataxia.
🧬

Genetic Associations

1
COQ8A (Biallelic Pathogenic Variant)
Show evidence (1 reference)
DOI:10.1002/ana.25751 SUPPORT Human Clinical
"Fifty‐nine patients (39 novel) with 44 pathogenic COQ8A variants (18 novel) were identified."
This multicenter cohort directly supports COQ8A as the causal gene.
💊

Treatments

1
Coenzyme Q10 supplementation
Action: coenzyme Q10 supplementation MAXO:0010012
Agent: coenzyme Q10 ↗
High-dose coenzyme Q10 replacement is the main disease-targeted therapy and can improve symptoms in a substantial subset of patients.
Mechanism Target:
RESTORES COQ8A-Dependent Coenzyme Q10 Deficiency — Replacement therapy addresses the primary ubiquinone deficiency state.
Show evidence (2 references)
DOI:10.3390/metabo12100955 SUPPORT Human Clinical
"COQ8A-ataxia is a potentially treatable condition with the supplementation of coenzyme Q10 as a main therapy;"
Review supports CoQ10 supplementation as replacement therapy for the primary coenzyme Q deficiency state.
DOI:10.1002/ana.25751 SUPPORT Human Clinical
"CoQ10 treatment led to improvement by clinical report in 14 of 30 patients, and by quantitative longitudinal assessments in 8 of 11 patients"
Cohort treatment-response data support CoQ10 as a disease-targeted mechanism intervention.
Show evidence (2 references)
DOI:10.3390/metabo12100955 SUPPORT Human Clinical
"COQ8A-ataxia is a potentially treatable condition with the supplementation of coenzyme Q10 as a main therapy;"
This directly supports coenzyme Q10 supplementation as the principal disease-specific therapy.
DOI:10.1002/ana.25751 SUPPORT Human Clinical
"CoQ10 treatment led to improvement by clinical report in 14 of 30 patients, and by quantitative longitudinal assessments in 8 of 11 patients"
This provides cohort-level evidence that CoQ10 supplementation can improve clinical outcomes in a sizable subset of patients.
🔬

Biochemical Markers

2
Coenzyme Q10 level (DECREASED)
Context: COQ8A/ADCK3 deficiency reduces CoQ10 content, which can be used as a biochemical readout of the primary coenzyme Q deficiency state.
Pathograph Readouts
Readout Of COQ8A-Dependent Coenzyme Q10 Deficiency Negative Diagnostic
Lower cellular or tissue CoQ10 reports the primary COQ8A-dependent biosynthetic defect.
Show evidence (1 reference)
PMID:26866375 SUPPORT In Vitro
"ADCK3 deficiency decreased cellular CoQ10 content."
Patient-derived cell studies directly document decreased cellular CoQ10 content after ADCK3 deficiency.
Serum lactate level (INCREASED)
Context: Elevated serum lactate is reported in COQ8A disease and provides a biochemical readout of mitochondrial respiratory-chain dysfunction.
Pathograph Readouts
Readout Of Impaired Oxidative Phosphorylation Positive Diagnostic
Elevated serum lactate reports impaired mitochondrial respiratory-chain energy metabolism.
Show evidence (2 references)
PMID:32743982 SUPPORT Human Clinical
"His serum lactate levels were elevated, and plasma CoQ10 concentrations were decreased."
Patient biochemical testing directly documents elevated serum lactate.
PMID:37476682 SUPPORT Human Clinical
"abnormal serum urea (49.4 mg/dL), lactate (7.5 mmol/L), and CoQ10 level (0.4 µg/mL)"
An independent COQ8A case report documents elevated lactate with low CoQ10.
🔀

Differential Diagnoses

2

Conditions with similar clinical presentations that must be differentiated from Autosomal Recessive Ataxia Due to Ubiquinone Deficiency:

Other mitochondrial diseases
Overlapping Features COQ8A-related ubiquinone-deficiency ataxia can overlap clinically with other mitochondrial disorders and should be separated by molecular testing and treatment-response considerations.
Distinguishing Features
  • COQ8A disease is a primary coenzyme Q10 biosynthesis disorder with potentially actionable supplementation.
  • Broader mitochondrial diseases may share ataxia and regression but do not necessarily reflect primary ubiquinone deficiency.
Show evidence (1 reference)
DOI:10.3390/metabo12100955 SUPPORT Human Clinical
"However, due to variable phenotype, it may be hard to distinguish from other mitochondrial diseases"
This directly supports other mitochondrial diseases as a core diagnostic differential.
Childhood-onset cerebellar ataxias
Overlapping Features The variable childhood presentation overlaps with a broader group of childhood-onset cerebellar ataxias that must be distinguished molecularly.
Distinguishing Features
  • COQ8A-related disease is a potentially treatable primary coenzyme Q10 deficiency.
  • Universal cerebellar atrophy and COQ8A pathogenic variants support this specific diagnosis.
Show evidence (1 reference)
DOI:10.3390/metabo12100955 SUPPORT Human Clinical
"and a wide spectrum of childhood-onset cerebellar ataxia."
This directly supports broader childhood-onset cerebellar ataxias as a major diagnostic differential class.
{ }

Source YAML

click to show 
name: Autosomal Recessive Ataxia Due to Ubiquinone Deficiency
creation_date: "2026-04-23T00:00:00Z"
updated_date: "2026-05-19T15:31:15Z"
category: Neurological Disorder
parents:
- Mendelian Disorder
- Neurological Disorder
disease_term:
  preferred_term: autosomal recessive ataxia due to ubiquinone deficiency
  term:
    id: MONDO:0012784
    label: autosomal recessive ataxia due to ubiquinone deficiency
has_subtypes:
- name: COQ8A-ataxia
  description: >-
    The best-characterized form of autosomal recessive ubiquinone-deficiency
    ataxia, also known as primary coenzyme Q10 deficiency-4, ARCA2, or SCAR9.
  evidence:
  - reference: DOI:10.3390/metabo12100955
    reference_title: COQ8A-Ataxia as a Manifestation of Primary Coenzyme Q Deficiency
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      COQ8A-ataxia is a mitochondrial disease in which a defect in coenzyme
      Q10 synthesis leads to dysfunction of the respiratory chain.
    explanation: >-
      This directly supports COQ8A-ataxia as the core mechanistic subtype
      within this MONDO disease concept.
pathophysiology:
- name: COQ8A-Dependent Coenzyme Q10 Deficiency
  description: >-
    Biallelic COQ8A dysfunction disrupts coenzyme Q10 homeostasis, producing a
    primary coenzyme Q10 deficiency state that underlies the disease.
  genes:
  - preferred_term: COQ8A
    term:
      id: hgnc:16812
      label: COQ8A
  biological_processes:
  - preferred_term: ubiquinone biosynthetic process
    term:
      id: GO:0006744
      label: ubiquinone biosynthetic process
    modifier: DECREASED
  chemical_entities:
  - preferred_term: coenzyme Q10
    term:
      id: CHEBI:46245
      label: coenzyme Q10
    modifier: DECREASED
  evidence:
  - reference: DOI:10.3390/metabo12100955
    reference_title: COQ8A-Ataxia as a Manifestation of Primary Coenzyme Q Deficiency
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      COQ8A-ataxia is a mitochondrial disease in which a defect in coenzyme
      Q10 synthesis leads to dysfunction of the respiratory chain.
    explanation: >-
      This directly supports the upstream metabolic defect in CoQ10
      biosynthesis caused by COQ8A deficiency.
  downstream:
  - target: Coenzyme Q10 level
    description: COQ8A deficiency lowers cellular CoQ10 content.
    causal_link_type: DIRECT
    evidence:
    - reference: PMID:26866375
      reference_title: "AarF Domain Containing Kinase 3 (ADCK3) Mutant Cells Display Signs of Oxidative Stress, Defects in Mitochondrial Homeostasis and Lysosomal Accumulation."
      supports: SUPPORT
      evidence_source: IN_VITRO
      snippet: "ADCK3 deficiency decreased cellular CoQ10 content."
      explanation: Patient-cell studies directly support reduced CoQ10 content downstream of ADCK3/COQ8A deficiency.
  - target: Impaired Oxidative Phosphorylation
    description: Reduced CoQ10 availability compromises mitochondrial energy transfer.
    causal_link_type: DIRECT
    evidence:
    - reference: DOI:10.3390/metabo12100955
      reference_title: COQ8A-Ataxia as a Manifestation of Primary Coenzyme Q Deficiency
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: >-
        COQ8A-ataxia is a mitochondrial disease in which a defect in coenzyme
        Q10 synthesis leads to dysfunction of the respiratory chain.
      explanation: >-
        Human clinical review directly links the CoQ10 synthesis defect to
        respiratory-chain dysfunction.
- name: Impaired Oxidative Phosphorylation
  description: >-
    Reduced coenzyme Q10 availability impairs respiratory-chain function and
    mitochondrial energy production, creating a mitochondrial ataxia phenotype.
  biological_processes:
  - preferred_term: oxidative phosphorylation
    term:
      id: GO:0006119
      label: oxidative phosphorylation
    modifier: DECREASED
  - preferred_term: mitochondrial electron transport, NADH to ubiquinone
    term:
      id: GO:0006120
      label: mitochondrial electron transport, NADH to ubiquinone
    modifier: DECREASED
  evidence:
  - reference: DOI:10.3390/metabo12100955
    reference_title: COQ8A-Ataxia as a Manifestation of Primary Coenzyme Q Deficiency
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      COQ8A-ataxia is a mitochondrial disease in which a defect in coenzyme
      Q10 synthesis leads to dysfunction of the respiratory chain.
    explanation: >-
      The same abstract directly links CoQ10 deficiency to respiratory-chain
      dysfunction, supporting impaired oxidative phosphorylation.
  downstream:
  - target: Progressive Cerebellar Neurodegeneration
    description: Energy failure drives selective cerebellar vulnerability and progressive ataxia.
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    evidence:
    - reference: DOI:10.3390/metabo12100955
      reference_title: COQ8A-Ataxia as a Manifestation of Primary Coenzyme Q Deficiency
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: >-
        The disease is usually present as childhood-onset progressive ataxia
        with developmental regression and cerebellar atrophy.
      explanation: >-
        Review supports progressive cerebellar ataxia and cerebellar atrophy as
        downstream manifestations of COQ8A-related respiratory-chain disease.
  - target: Oxidative Stress and Mitochondrial Homeostasis Defects
    description: >-
      ADCK3-deficient patient cells show oxidative stress and disordered
      mitochondrial homeostasis downstream of impaired CoQ10-dependent
      mitochondrial function.
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    intermediate_mechanisms:
    - reduced CoQ10-dependent respiratory-chain electron transfer
    evidence:
    - reference: PMID:26866375
      reference_title: "AarF Domain Containing Kinase 3 (ADCK3) Mutant Cells Display Signs of Oxidative Stress, Defects in Mitochondrial Homeostasis and Lysosomal Accumulation."
      supports: SUPPORT
      evidence_source: IN_VITRO
      snippet: |-
        lines derived from ARCA-2 patients display signs of oxidative stress, defects in
        mitochondrial homeostasis and increases in lysosomal content.
      explanation: >-
        Patient-derived cell data support oxidative-stress and mitochondrial
        homeostasis abnormalities as downstream cellular consequences.
  - target: COQ8A-Related Multisystem Brain Disease
    description: >-
      Respiratory-chain dysfunction in COQ8A disease manifests as a progressive
      multisystem neurologic syndrome rather than isolated cerebellar ataxia.
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    intermediate_mechanisms:
    - neuronal energy failure from impaired mitochondrial respiratory-chain function
    evidence:
    - reference: PMID:31621627
      reference_title: "Dystonia-Ataxia with early handwriting deterioration in COQ8A mutation carriers: A case series and literature review."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "history is characterized by a progression to a multisystem brain disease"
      explanation: >-
        Clinical review supports progression beyond isolated ataxia to
        multisystem brain disease.
  - target: Systemic Mitochondrial Energy Limitation
    description: >-
      CoQ10-dependent respiratory-chain dysfunction can extend beyond the
      cerebellum and limit systemic exercise tolerance.
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    intermediate_mechanisms:
    - reduced mitochondrial ATP production during exertion
    evidence:
    - reference: DOI:10.1002/ana.25751
      reference_title: "Clinico‐Genetic, Imaging and Molecular Delineation of <scp><i>COQ8A</i></scp>‐Ataxia: A Multicenter Study of 59 Patients"
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "to exercise intolerance (25%)"
      explanation: >-
        The multicenter cohort documents exercise intolerance as a recurrent
        systemic feature in COQ8A disease.
  - target: Serum lactate level
    description: >-
      Respiratory-chain dysfunction in COQ8A disease can be accompanied by
      elevated circulating lactate.
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    intermediate_mechanisms:
    - impaired mitochondrial pyruvate oxidation with compensatory lactate production
    evidence:
    - reference: PMID:32743982
      reference_title: Primary coenzyme Q10 deficiency due to COQ8A gene mutations.
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "His serum lactate levels were elevated, and plasma CoQ10 concentrations were decreased."
      explanation: >-
        Patient biochemical data support elevated serum lactate as a readout
        associated with COQ8A-related respiratory-chain disease.
- name: Oxidative Stress and Mitochondrial Homeostasis Defects
  description: >-
    ADCK3/COQ8A-deficient patient cells have oxidative stress, altered
    mitochondrial homeostasis, and lysosomal accumulation, providing a cellular
    stress pathway between CoQ10-dependent respiratory-chain dysfunction and
    neural vulnerability.
  biological_processes:
  - preferred_term: response to oxidative stress
    term:
      id: GO:0006979
      label: response to oxidative stress
    modifier: INCREASED
  evidence:
  - reference: PMID:26866375
    reference_title: "AarF Domain Containing Kinase 3 (ADCK3) Mutant Cells Display Signs of Oxidative Stress, Defects in Mitochondrial Homeostasis and Lysosomal Accumulation."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: |-
      lines derived from ARCA-2 patients display signs of oxidative stress, defects in
      mitochondrial homeostasis and increases in lysosomal content.
    explanation: >-
      Patient-derived cell studies support oxidative stress as a cellular
      consequence of ADCK3/COQ8A deficiency.
  downstream:
  - target: Progressive Cerebellar Neurodegeneration
    description: >-
      Oxidative and mitochondrial homeostasis stress provide a plausible
      cellular route to selective cerebellar injury in COQ8A disease.
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    evidence:
    - reference: PMID:27499294
      reference_title: Cerebellar Ataxia and Coenzyme Q Deficiency through Loss of Unorthodox Kinase Activity.
      supports: SUPPORT
      evidence_source: MODEL_ORGANISM
      snippet: |-
        mice lacking COQ8A develop a slowly progressive cerebellar ataxia linked to
        Purkinje cell dysfunction and mild exercise intolerance, recapitulating ARCA2.
      explanation: >-
        Mouse data support cerebellar Purkinje-cell vulnerability downstream of
        COQ8A loss, consistent with a cellular-stress route to cerebellar
        degeneration.
- name: COQ8A-Related Multisystem Brain Disease
  description: >-
    COQ8A disease can progress to a multisystem brain syndrome that includes
    epilepsy, cognitive impairment, developmental regression, and hyperkinetic
    movement disorders in addition to cerebellar ataxia.
  evidence:
  - reference: PMID:31621627
    reference_title: "Dystonia-Ataxia with early handwriting deterioration in COQ8A mutation carriers: A case series and literature review."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "history is characterized by a progression to a multisystem brain disease"
    explanation: >-
      Clinical review characterizes COQ8A disease as progressive multisystem
      brain involvement.
  downstream:
  - target: Seizure
    description: Multisystem brain involvement in COQ8A disease includes epilepsy.
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    intermediate_mechanisms:
    - mitochondrial neuronal energy failure and network hyperexcitability
    evidence:
    - reference: DOI:10.1002/ana.25751
      reference_title: "Clinico‐Genetic, Imaging and Molecular Delineation of <scp><i>COQ8A</i></scp>‐Ataxia: A Multicenter Study of 59 Patients"
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "with complicating features ranging from epilepsy (32%)"
      explanation: The cohort directly reports epilepsy as a complicating feature.
  - target: Cognitive Impairment
    description: Multisystem brain involvement commonly includes cognitive impairment.
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    intermediate_mechanisms:
    - chronic mitochondrial neuronal dysfunction
    evidence:
    - reference: DOI:10.1002/ana.25751
      reference_title: "Clinico‐Genetic, Imaging and Molecular Delineation of <scp><i>COQ8A</i></scp>‐Ataxia: A Multicenter Study of 59 Patients"
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "cognitive impairment (49%)"
      explanation: The cohort directly reports cognitive impairment in nearly half of patients.
  - target: Developmental Regression
    description: Childhood-onset COQ8A disease can include developmental regression.
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    intermediate_mechanisms:
    - early-life mitochondrial neuronal dysfunction
    evidence:
    - reference: DOI:10.3390/metabo12100955
      reference_title: COQ8A-Ataxia as a Manifestation of Primary Coenzyme Q Deficiency
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: >-
        The disease is usually present as childhood-onset progressive ataxia
        with developmental regression and cerebellar atrophy.
      explanation: The review explicitly includes developmental regression in the usual presentation.
  - target: COQ8A-Related Hyperkinetic Motor Circuit Dysfunction
    description: >-
      Multisystem brain involvement includes hyperkinetic movement disorders,
      especially dystonia and myoclonus.
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    intermediate_mechanisms:
    - motor network dysfunction in COQ8A-related multisystem brain disease
    evidence:
    - reference: DOI:10.1002/ana.25751
      reference_title: "Clinico‐Genetic, Imaging and Molecular Delineation of <scp><i>COQ8A</i></scp>‐Ataxia: A Multicenter Study of 59 Patients"
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: >-
        hyperkinetic movement disorders (41%), including dystonia and myoclonus
        as presenting symptoms
      explanation: The cohort identifies hyperkinetic movement disorders, dystonia, and myoclonus as COQ8A features.
- name: COQ8A-Related Hyperkinetic Motor Circuit Dysfunction
  description: >-
    COQ8A disease can involve motor circuits beyond the cerebellum, producing
    hyperkinetic movement disorders such as dystonia and myoclonus.
  evidence:
  - reference: DOI:10.1002/ana.25751
    reference_title: "Clinico‐Genetic, Imaging and Molecular Delineation of <scp><i>COQ8A</i></scp>‐Ataxia: A Multicenter Study of 59 Patients"
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      hyperkinetic movement disorders (41%), including dystonia and myoclonus
      as presenting symptoms
    explanation: The cohort directly supports hyperkinetic movement disorder involvement.
  downstream:
  - target: Hyperkinetic Movement Disorder
    description: Motor-circuit involvement manifests as hyperkinetic movement disorder.
    causal_link_type: DIRECT
    evidence:
    - reference: DOI:10.1002/ana.25751
      reference_title: "Clinico‐Genetic, Imaging and Molecular Delineation of <scp><i>COQ8A</i></scp>‐Ataxia: A Multicenter Study of 59 Patients"
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "hyperkinetic movement disorders (41%)"
      explanation: The cohort directly reports hyperkinetic movement disorders.
  - target: Dystonia
    description: Dystonia is a specific hyperkinetic manifestation of COQ8A disease.
    causal_link_type: DIRECT
    evidence:
    - reference: DOI:10.1002/ana.25751
      reference_title: "Clinico‐Genetic, Imaging and Molecular Delineation of <scp><i>COQ8A</i></scp>‐Ataxia: A Multicenter Study of 59 Patients"
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: >-
        including dystonia and myoclonus as presenting symptoms
      explanation: The cohort directly names dystonia as a presenting symptom.
  - target: Myoclonus
    description: Myoclonus is a specific hyperkinetic manifestation of COQ8A disease.
    causal_link_type: DIRECT
    evidence:
    - reference: DOI:10.1002/ana.25751
      reference_title: "Clinico‐Genetic, Imaging and Molecular Delineation of <scp><i>COQ8A</i></scp>‐Ataxia: A Multicenter Study of 59 Patients"
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: >-
        including dystonia and myoclonus as presenting symptoms
      explanation: The cohort directly names myoclonus as a presenting symptom.
- name: Systemic Mitochondrial Energy Limitation
  description: >-
    CoQ10-dependent respiratory-chain dysfunction can impair energy production
    during exertion, producing exercise intolerance in a subset of patients.
  biological_processes:
  - preferred_term: oxidative phosphorylation
    term:
      id: GO:0006119
      label: oxidative phosphorylation
    modifier: DECREASED
  evidence:
  - reference: DOI:10.1002/ana.25751
    reference_title: "Clinico‐Genetic, Imaging and Molecular Delineation of <scp><i>COQ8A</i></scp>‐Ataxia: A Multicenter Study of 59 Patients"
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "to exercise intolerance (25%)"
    explanation: The multicenter cohort documents exercise intolerance as a recurrent non-cerebellar feature.
  downstream:
  - target: Exercise Intolerance
    description: Systemic mitochondrial energy limitation manifests clinically as exercise intolerance.
    causal_link_type: DIRECT
    evidence:
    - reference: DOI:10.1002/ana.25751
      reference_title: "Clinico‐Genetic, Imaging and Molecular Delineation of <scp><i>COQ8A</i></scp>‐Ataxia: A Multicenter Study of 59 Patients"
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "to exercise intolerance (25%)"
      explanation: The cohort directly reports exercise intolerance.
- name: Progressive Cerebellar Neurodegeneration
  description: >-
    COQ8A-related ubiquinone deficiency preferentially injures cerebellar
    systems, producing early-onset progressive cerebellar ataxia with
    universal cerebellar atrophy on MRI in the largest cohort.
  cell_types:
  - preferred_term: Purkinje cell
    term:
      id: CL:0000121
      label: Purkinje cell
  locations:
  - preferred_term: cerebellum
    term:
      id: UBERON:0002037
      label: cerebellum
  evidence:
  - reference: DOI:10.1002/ana.25751
    reference_title: "Clinico‐Genetic, Imaging and Molecular Delineation of <scp><i>COQ8A</i></scp>‐Ataxia: A Multicenter Study of 59 Patients"
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      COQ8A‐ataxia presented as variable multisystemic, early‐onset
      cerebellar ataxia,
    explanation: >-
      This supports cerebellar neurodegeneration as the dominant clinical
      and anatomical disease axis.
  downstream:
  - target: Ataxia
    description: Cerebellar system degeneration produces the core ataxic phenotype.
    causal_link_type: DIRECT
    evidence:
    - reference: DOI:10.1002/ana.25751
      reference_title: "Clinico‐Genetic, Imaging and Molecular Delineation of <scp><i>COQ8A</i></scp>‐Ataxia: A Multicenter Study of 59 Patients"
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: >-
        COQ8A‐ataxia presented as variable multisystemic, early‐onset
        cerebellar ataxia,
      explanation: >-
        Cohort evidence identifies early-onset cerebellar ataxia as the central
        manifestation of cerebellar involvement.
  - target: Cerebellar Atrophy
    description: Structural cerebellar volume loss is the imaging hallmark of disease.
    causal_link_type: DIRECT
    evidence:
    - reference: DOI:10.1002/ana.25751
      reference_title: "Clinico‐Genetic, Imaging and Molecular Delineation of <scp><i>COQ8A</i></scp>‐Ataxia: A Multicenter Study of 59 Patients"
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: Cerebellar atrophy was universal on MRI (100%),
      explanation: >-
        Cohort evidence supports cerebellar atrophy as the universal structural
        consequence of cerebellar disease.
  - target: Dysarthria
    description: Cerebellar system involvement can produce dysarthria in COQ8A disease.
    causal_link_type: DIRECT
    evidence:
    - reference: PMID:32743982
      reference_title: Primary coenzyme Q10 deficiency due to COQ8A gene mutations.
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "Neurological examination revealed mild dysarthria, overt head tremor, bilateral dysmetria, and intention tremor on nose‐finger and heel‐shin tests"
      explanation: >-
        Clinical examination directly documents dysarthria alongside cerebellar
        motor signs in COQ8A disease.
  - target: Tremor
    description: Cerebellar system involvement can include head and intention tremor.
    causal_link_type: DIRECT
    evidence:
    - reference: PMID:32743982
      reference_title: Primary coenzyme Q10 deficiency due to COQ8A gene mutations.
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "Neurological examination revealed mild dysarthria, overt head tremor, bilateral dysmetria, and intention tremor on nose‐finger and heel‐shin tests"
      explanation: >-
        Clinical examination directly documents head and intention tremor with
        dysmetria in COQ8A disease.
phenotypes:
- name: Ataxia
  description: >-
    Early-onset progressive cerebellar ataxia is the defining neurologic
    phenotype of this disorder.
  frequency: VERY_FREQUENT
  phenotype_term:
    preferred_term: progressive cerebellar ataxia
    term:
      id: HP:0002073
      label: Progressive cerebellar ataxia
    clinical_course: PROGRESSIVE
    onset:
      onset_category: CHILDHOOD
  evidence:
  - reference: DOI:10.1002/ana.25751
    reference_title: "Clinico‐Genetic, Imaging and Molecular Delineation of <scp><i>COQ8A</i></scp>‐Ataxia: A Multicenter Study of 59 Patients"
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      COQ8A‐ataxia presented as variable multisystemic, early‐onset
      cerebellar ataxia,
    explanation: >-
      Directly supports ataxia as the core and defining disease phenotype.
- name: Dysarthria
  description: >-
    Dysarthria is a recurrent speech manifestation of COQ8A disease and can
    accompany cerebellar motor findings.
  frequency: FREQUENT
  phenotype_term:
    preferred_term: dysarthria
    term:
      id: HP:0001260
      label: Dysarthria
  evidence:
  - reference: PMID:32743982
    reference_title: Primary coenzyme Q10 deficiency due to COQ8A gene mutations.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Neurological examination revealed mild dysarthria, overt head tremor, bilateral dysmetria, and intention tremor on nose‐finger and heel‐shin tests"
    explanation: >-
      Clinical examination directly documents dysarthria in a patient with
      COQ8A disease.
  - reference: PMID:31621627
    reference_title: "Dystonia-Ataxia with early handwriting deterioration in COQ8A mutation carriers: A case series and literature review."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: |-
      clinical phenotype
      characterized by slowly progressive or static writing difficulties, focal
      dystonia, and speech disorder
    explanation: >-
      The clinical review supports speech disorder as a recurring feature in
      COQ8A mutation carriers.
- name: Tremor
  description: >-
    Head and intention tremor can occur in COQ8A disease, often with other
    cerebellar motor signs.
  frequency: FREQUENT
  phenotype_term:
    preferred_term: tremor
    term:
      id: HP:0001337
      label: Tremor
  evidence:
  - reference: PMID:32743982
    reference_title: Primary coenzyme Q10 deficiency due to COQ8A gene mutations.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Neurological examination revealed mild dysarthria, overt head tremor, bilateral dysmetria, and intention tremor on nose‐finger and heel‐shin tests"
    explanation: >-
      Clinical examination directly documents overt head tremor and intention
      tremor in COQ8A disease.
- name: Cerebellar Atrophy
  description: >-
    Cerebellar atrophy is the characteristic structural neuroimaging
    abnormality and was universal in the largest reported cohort.
  frequency: VERY_FREQUENT
  phenotype_term:
    preferred_term: cerebellar atrophy
    term:
      id: HP:0001272
      label: Cerebellar atrophy
  evidence:
  - reference: DOI:10.1002/ana.25751
    reference_title: "Clinico‐Genetic, Imaging and Molecular Delineation of <scp><i>COQ8A</i></scp>‐Ataxia: A Multicenter Study of 59 Patients"
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Cerebellar atrophy was universal on MRI (100%),
    explanation: >-
      This directly supports cerebellar atrophy as a universal imaging
      phenotype in the cohort.
- name: Seizure
  description: >-
    Epilepsy occurs in a clinically important subset of patients with
    COQ8A-related ubiquinone-deficiency ataxia.
  frequency: FREQUENT
  phenotype_term:
    preferred_term: seizure
    term:
      id: HP:0001250
      label: Seizure
  evidence:
  - reference: DOI:10.1002/ana.25751
    reference_title: "Clinico‐Genetic, Imaging and Molecular Delineation of <scp><i>COQ8A</i></scp>‐Ataxia: A Multicenter Study of 59 Patients"
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      with complicating features ranging from epilepsy (32%) and cognitive
      impairment (49%)
    explanation: >-
      This supports seizure/epilepsy as a frequent complicating phenotype.
- name: Cognitive Impairment
  description: >-
    Cognitive impairment is common and contributes to the multisystemic
    neurodevelopmental burden of disease.
  frequency: FREQUENT
  phenotype_term:
    preferred_term: cognitive impairment
    term:
      id: HP:0100543
      label: Cognitive impairment
  evidence:
  - reference: DOI:10.1002/ana.25751
    reference_title: "Clinico‐Genetic, Imaging and Molecular Delineation of <scp><i>COQ8A</i></scp>‐Ataxia: A Multicenter Study of 59 Patients"
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      with complicating features ranging from epilepsy (32%) and cognitive
      impairment (49%)
    explanation: >-
      This directly supports cognitive impairment as a common multisystem
      manifestation.
- name: Developmental Regression
  description: >-
    Developmental regression can occur in childhood-onset COQ8A ataxia as part
    of the broader neurodevelopmental presentation.
  frequency: FREQUENT
  phenotype_term:
    preferred_term: developmental regression
    term:
      id: HP:0002376
      label: Developmental regression
    onset:
      onset_category: CHILDHOOD
  evidence:
  - reference: DOI:10.3390/metabo12100955
    reference_title: COQ8A-Ataxia as a Manifestation of Primary Coenzyme Q Deficiency
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      The disease is usually present as childhood-onset progressive ataxia with
      developmental regression and cerebellar atrophy.
    explanation: >-
      Review directly names developmental regression as part of the usual
      childhood-onset presentation.
- name: Exercise Intolerance
  description: >-
    Exercise intolerance reflects broader mitochondrial energy failure beyond
    the cerebellar syndrome.
  frequency: OCCASIONAL
  phenotype_term:
    preferred_term: exercise intolerance
    term:
      id: HP:0003546
      label: Exercise intolerance
  evidence:
  - reference: DOI:10.1002/ana.25751
    reference_title: "Clinico‐Genetic, Imaging and Molecular Delineation of <scp><i>COQ8A</i></scp>‐Ataxia: A Multicenter Study of 59 Patients"
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      with complicating features ranging from epilepsy (32%) and cognitive
      impairment (49%) to exercise intolerance (25%)
    explanation: >-
      This directly supports exercise intolerance as a recurrent
      non-cerebellar phenotype.
- name: Hyperkinetic Movement Disorder
  description: >-
    Hyperkinetic movement disorders, including dystonia and myoclonus, occur
    in a substantial subset of COQ8A-ataxia patients.
  frequency: FREQUENT
  phenotype_term:
    preferred_term: hyperkinetic movements
    term:
      id: HP:0002487
      label: Hyperkinetic movements
  evidence:
  - reference: DOI:10.1002/ana.25751
    reference_title: "Clinico‐Genetic, Imaging and Molecular Delineation of <scp><i>COQ8A</i></scp>‐Ataxia: A Multicenter Study of 59 Patients"
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      hyperkinetic movement disorders (41%), including dystonia and
      myoclonus as presenting symptoms
    explanation: >-
      This directly supports hyperkinetic movement disorders as a frequent
      phenotype in COQ8A-ataxia.
- name: Dystonia
  description: >-
    Dystonia is one of the explicitly reported hyperkinetic presenting
    movement disorders in COQ8A-related ubiquinone-deficiency ataxia.
  frequency: FREQUENT
  phenotype_term:
    preferred_term: dystonia
    term:
      id: HP:0001332
      label: Dystonia
  evidence:
  - reference: DOI:10.1002/ana.25751
    reference_title: "Clinico‐Genetic, Imaging and Molecular Delineation of <scp><i>COQ8A</i></scp>‐Ataxia: A Multicenter Study of 59 Patients"
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      hyperkinetic movement disorders (41%), including dystonia and
      myoclonus as presenting symptoms
    explanation: >-
      Directly names dystonia as a presenting symptom within the frequent
      hyperkinetic movement disorder group.
- name: Myoclonus
  description: >-
    Myoclonus is one of the explicitly reported hyperkinetic presenting
    movement disorders in COQ8A-related ubiquinone-deficiency ataxia.
  frequency: FREQUENT
  phenotype_term:
    preferred_term: myoclonus
    term:
      id: HP:0001336
      label: Myoclonus
  evidence:
  - reference: DOI:10.1002/ana.25751
    reference_title: "Clinico‐Genetic, Imaging and Molecular Delineation of <scp><i>COQ8A</i></scp>‐Ataxia: A Multicenter Study of 59 Patients"
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      hyperkinetic movement disorders (41%), including dystonia and
      myoclonus as presenting symptoms
    explanation: >-
      Directly names myoclonus as a presenting symptom within the frequent
      hyperkinetic movement disorder group.
diagnosis:
- name: Molecular genetic testing
  description: >-
    Molecular confirmation of biallelic COQ8A variants is central to
    diagnosing this treatable mitochondrial ataxia.
  results: >-
    Detection of pathogenic COQ8A variants confirms the molecular diagnosis
    and distinguishes this disorder from broader childhood-onset ataxia syndromes.
  diagnosis_term:
    preferred_term: molecular genetic testing
    term:
      id: MAXO:0000533
      label: molecular genetic testing
  evidence:
  - reference: DOI:10.1002/ana.25751
    reference_title: "Clinico‐Genetic, Imaging and Molecular Delineation of <scp><i>COQ8A</i></scp>‐Ataxia: A Multicenter Study of 59 Patients"
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Fifty‐nine patients (39 novel) with 44 pathogenic COQ8A variants (18
      novel) were identified.
    explanation: >-
      This directly supports variant-level molecular confirmation as the
      core diagnostic approach.
- name: Brain MRI
  description: >-
    Brain MRI is used to identify the characteristic cerebellar atrophy and
    related structural abnormalities.
  results: >-
    Cerebellar atrophy strongly supports the diagnosis and helps define the
    structural burden of disease.
  diagnosis_term:
    preferred_term: magnetic resonance imaging procedure
    term:
      id: MAXO:0000424
      label: magnetic resonance imaging procedure
  evidence:
  - reference: DOI:10.1002/ana.25751
    reference_title: "Clinico‐Genetic, Imaging and Molecular Delineation of <scp><i>COQ8A</i></scp>‐Ataxia: A Multicenter Study of 59 Patients"
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Cerebellar atrophy was universal on MRI (100%),
    explanation: >-
      This directly supports MRI as the key structural diagnostic modality.
differential_diagnoses:
- name: Other mitochondrial diseases
  description: >-
    COQ8A-related ubiquinone-deficiency ataxia can overlap clinically with
    other mitochondrial disorders and should be separated by molecular testing
    and treatment-response considerations.
  distinguishing_features:
  - COQ8A disease is a primary coenzyme Q10 biosynthesis disorder with potentially actionable supplementation.
  - Broader mitochondrial diseases may share ataxia and regression but do not necessarily reflect primary ubiquinone deficiency.
  evidence:
  - reference: DOI:10.3390/metabo12100955
    reference_title: COQ8A-Ataxia as a Manifestation of Primary Coenzyme Q Deficiency
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      However, due to variable phenotype, it may be hard to distinguish
      from other mitochondrial diseases
    explanation: >-
      This directly supports other mitochondrial diseases as a core
      diagnostic differential.
- name: Childhood-onset cerebellar ataxias
  description: >-
    The variable childhood presentation overlaps with a broader group of
    childhood-onset cerebellar ataxias that must be distinguished
    molecularly.
  distinguishing_features:
  - COQ8A-related disease is a potentially treatable primary coenzyme Q10 deficiency.
  - Universal cerebellar atrophy and COQ8A pathogenic variants support this specific diagnosis.
  evidence:
  - reference: DOI:10.3390/metabo12100955
    reference_title: COQ8A-Ataxia as a Manifestation of Primary Coenzyme Q Deficiency
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      and a wide spectrum of childhood-onset cerebellar ataxia.
    explanation: >-
      This directly supports broader childhood-onset cerebellar ataxias as a
      major diagnostic differential class.
genetic:
- name: COQ8A
  gene_term:
    preferred_term: COQ8A
    term:
      id: hgnc:16812
      label: COQ8A
  association: Biallelic Pathogenic Variant
  evidence:
  - reference: DOI:10.1002/ana.25751
    reference_title: "Clinico‐Genetic, Imaging and Molecular Delineation of <scp><i>COQ8A</i></scp>‐Ataxia: A Multicenter Study of 59 Patients"
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Fifty‐nine patients (39 novel) with 44 pathogenic COQ8A variants (18
      novel) were identified.
    explanation: >-
      This multicenter cohort directly supports COQ8A as the causal gene.
  notes: >-
    COQ8A is also known as ADCK3 and CABC1 in the disease literature.
treatments:
- name: Coenzyme Q10 supplementation
  description: >-
    High-dose coenzyme Q10 replacement is the main disease-targeted therapy
    and can improve symptoms in a substantial subset of patients.
  treatment_term:
    preferred_term: coenzyme Q10 supplementation
    term:
      id: MAXO:0010012
      label: coenzyme Q10 supplementation
    therapeutic_agent:
    - preferred_term: coenzyme Q10
      term:
        id: CHEBI:46245
        label: coenzyme Q10
  target_mechanisms:
  - target: COQ8A-Dependent Coenzyme Q10 Deficiency
    treatment_effect: RESTORES
    description: Replacement therapy addresses the primary ubiquinone deficiency state.
    evidence:
    - reference: DOI:10.3390/metabo12100955
      reference_title: COQ8A-Ataxia as a Manifestation of Primary Coenzyme Q Deficiency
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: >-
        COQ8A-ataxia is a potentially treatable condition with the
        supplementation of coenzyme Q10 as a main therapy;
      explanation: >-
        Review supports CoQ10 supplementation as replacement therapy for the
        primary coenzyme Q deficiency state.
    - reference: DOI:10.1002/ana.25751
      reference_title: "Clinico‐Genetic, Imaging and Molecular Delineation of <scp><i>COQ8A</i></scp>‐Ataxia: A Multicenter Study of 59 Patients"
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: >-
        CoQ10 treatment led to improvement by clinical report in 14 of 30
        patients, and by quantitative longitudinal assessments in 8 of 11
        patients
      explanation: >-
        Cohort treatment-response data support CoQ10 as a disease-targeted
        mechanism intervention.
  evidence:
  - reference: DOI:10.3390/metabo12100955
    reference_title: COQ8A-Ataxia as a Manifestation of Primary Coenzyme Q Deficiency
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      COQ8A-ataxia is a potentially treatable condition with the
      supplementation of coenzyme Q10 as a main therapy;
    explanation: >-
      This directly supports coenzyme Q10 supplementation as the principal
      disease-specific therapy.
  - reference: DOI:10.1002/ana.25751
    reference_title: "Clinico‐Genetic, Imaging and Molecular Delineation of <scp><i>COQ8A</i></scp>‐Ataxia: A Multicenter Study of 59 Patients"
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      CoQ10 treatment led to improvement by clinical report in 14 of 30
      patients, and by quantitative longitudinal assessments in 8 of 11
      patients
    explanation: >-
      This provides cohort-level evidence that CoQ10 supplementation can
      improve clinical outcomes in a sizable subset of patients.
biochemical:
- name: Coenzyme Q10 level
  presence: DECREASED
  readouts:
  - target: COQ8A-Dependent Coenzyme Q10 Deficiency
    relationship: READOUT_OF
    direction: NEGATIVE
    endpoint_context: DIAGNOSTIC
    interpretation: Lower cellular or tissue CoQ10 reports the primary COQ8A-dependent biosynthetic defect.
  context: >-
    COQ8A/ADCK3 deficiency reduces CoQ10 content, which can be used as a
    biochemical readout of the primary coenzyme Q deficiency state.
  biomarker_term:
    preferred_term: coenzyme Q10
    term:
      id: CHEBI:46245
      label: coenzyme Q10
  evidence:
  - reference: PMID:26866375
    reference_title: "AarF Domain Containing Kinase 3 (ADCK3) Mutant Cells Display Signs of Oxidative Stress, Defects in Mitochondrial Homeostasis and Lysosomal Accumulation."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "ADCK3 deficiency decreased cellular CoQ10 content."
    explanation: Patient-derived cell studies directly document decreased cellular CoQ10 content after ADCK3 deficiency.
- name: Serum lactate level
  presence: INCREASED
  readouts:
  - target: Impaired Oxidative Phosphorylation
    relationship: READOUT_OF
    direction: POSITIVE
    endpoint_context: DIAGNOSTIC
    interpretation: Elevated serum lactate reports impaired mitochondrial respiratory-chain energy metabolism.
  context: >-
    Elevated serum lactate is reported in COQ8A disease and provides a
    biochemical readout of mitochondrial respiratory-chain dysfunction.
  biomarker_term:
    preferred_term: lactate
    term:
      id: CHEBI:24996
      label: lactate
  evidence:
  - reference: PMID:32743982
    reference_title: Primary coenzyme Q10 deficiency due to COQ8A gene mutations.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "His serum lactate levels were elevated, and plasma CoQ10 concentrations were decreased."
    explanation: Patient biochemical testing directly documents elevated serum lactate.
  - reference: PMID:37476682
    reference_title: "Adolescence Onset Primary Coenzyme Q10 Deficiency With Rare CoQ8A Gene Mutation: A Case Report and Review of Literature."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: |-
      abnormal serum
      urea (49.4 mg/dL), lactate (7.5 mmol/L), and CoQ10 level (0.4 µg/mL)
    explanation: An independent COQ8A case report documents elevated lactate with low CoQ10.
clinical_trials: []
datasets: []
references:
- reference: DOI:10.1002/ana.25751
  title: "Clinico‐Genetic, Imaging and Molecular Delineation of <scp><i>COQ8A</i></scp>‐Ataxia: A Multicenter Study of 59 Patients"
  findings:
  - statement: 'Clinico‐Genetic, Imaging and Molecular Delineation of <scp><i>COQ8A</i></scp>‐Ataxia: A Multicenter Study of 59 Patients'
    supporting_text: To foster trial‐readiness of coenzyme Q8A (COQ8A)‐ataxia, we map the clinicogenetic, molecular, and neuroimaging spectrum of COQ8A‐ataxia in a large worldwide cohort, and provide first progression data, including treatment response to coenzyme Q10 (CoQ10).MethodsCross‐modal analysis of a multicenter cohort of 59 COQ8A patients, including genotype–phenotype correlations, 3D‐protein modeling, in vitro mutation analyses, magnetic resonance imaging (MRI) markers, disease progression, and CoQ10 response data.ResultsFifty‐nine patients (39 novel) with 44 pathogenic COQ8A variants (18 novel) were identified.
  found_in:
  - Autosomal_Recessive_Ataxia_Due_to_Ubiquinone_Deficiency-deep-research-falcon.md
- reference: DOI:10.3390/metabo12100955
  title: COQ8A-Ataxia as a Manifestation of Primary Coenzyme Q Deficiency
  findings:
  - statement: COQ8A-ataxia is a mitochondrial disease in which a defect in coenzyme Q10 synthesis leads to dysfunction of the respiratory chain.
    supporting_text: COQ8A-ataxia is a mitochondrial disease in which a defect in coenzyme Q10 synthesis leads to dysfunction of the respiratory chain.
  found_in:
  - Autosomal_Recessive_Ataxia_Due_to_Ubiquinone_Deficiency-deep-research-falcon.md
- reference: DOI:10.3390/jcm13082391
  title: Primary Coenzyme Q10 Deficiency-Related Ataxias
  findings:
  - statement: Cerebellar ataxia is a neurological syndrome characterized by the imbalance (e.g., truncal ataxia, gait ataxia) and incoordination of limbs while executing a task (dysmetria), caused by the dysfunction of the cerebellum or its connections.
    supporting_text: Cerebellar ataxia is a neurological syndrome characterized by the imbalance (e.g., truncal ataxia, gait ataxia) and incoordination of limbs while executing a task (dysmetria), caused by the dysfunction of the cerebellum or its connections.
  found_in:
  - Autosomal_Recessive_Ataxia_Due_to_Ubiquinone_Deficiency-deep-research-falcon.md
- reference: DOI:10.1007/s11064-019-02786-5
  title: Primary Coenzyme Q deficiency Due to Novel ADCK3 Variants, Studies in Fibroblasts and Review of Literature
  found_in:
  - Autosomal_Recessive_Ataxia_Due_to_Ubiquinone_Deficiency-deep-research-falcon.md
  - Autosomal_Recessive_Ataxia_Due_to_Ubiquinone_Deficiency-deep-research-openscientist.md
  findings:
  - statement: Primary Coenzyme Q deficiency Due to Novel ADCK3 Variants, Studies in Fibroblasts and Review of Literature
    supporting_text: Primary Coenzyme Q deficiency Due to Novel ADCK3 Variants, Studies in Fibroblasts and Review of Literature
- reference: DOI:10.1186/s13041-022-00900-3
  title: Loss of Drosophila Coq8 results in impaired survival, locomotor deficits and photoreceptor degeneration
  found_in:
  - Autosomal_Recessive_Ataxia_Due_to_Ubiquinone_Deficiency-deep-research-falcon.md
  - Autosomal_Recessive_Ataxia_Due_to_Ubiquinone_Deficiency-deep-research-openscientist.md
  findings:
  - statement: Coenzyme Q8A encodes the homologue of yeast coq8, an ATPase that is required for the biosynthesis of Coenzyme Q10, an essential component of the electron transport chain.
    supporting_text: Coenzyme Q8A encodes the homologue of yeast coq8, an ATPase that is required for the biosynthesis of Coenzyme Q10, an essential component of the electron transport chain.
- reference: DOI:10.1212/nxg.0000000000200209
  title: Clinical Features, Biochemistry, Imaging, and Treatment Response in a Single-Center Cohort With Coenzyme Q <sub>10</sub> Biosynthesis Disorders
  found_in:
  - Autosomal_Recessive_Ataxia_Due_to_Ubiquinone_Deficiency-deep-research-falcon.md
  findings:
  - statement: Clinical Features, Biochemistry, Imaging, and Treatment Response in a Single-Center Cohort With Coenzyme Q <sub>10</sub> Biosynthesis Disorders
    supporting_text: Clinical Features, Biochemistry, Imaging, and Treatment Response in a Single-Center Cohort With Coenzyme Q <sub>10</sub> Biosynthesis Disorders
- reference: PMID:10760477
  title: Genetic evidence for a multi-subunit complex in the O-methyltransferase steps of coenzyme Q biosynthesis.
  found_in:
  - Autosomal_Recessive_Ataxia_Due_to_Ubiquinone_Deficiency-deep-research-openscientist.md
  findings:
  - statement: '2000 Apr 12;1484(2-3):287-97. doi: 10.1016/s1388-1981(00)00019-6.'
    supporting_text: '2000 Apr 12;1484(2-3):287-97. doi: 10.1016/s1388-1981(00)00019-6.'
- reference: PMID:15710863
  title: Isolated mitochondrial myopathy associated with muscle coenzyme Q10 deficiency.
  found_in:
  - Autosomal_Recessive_Ataxia_Due_to_Ubiquinone_Deficiency-deep-research-openscientist.md
  findings:
  - statement: Primary coenzyme Q(10) (CoQ(10)) deficiency is rare.
    supporting_text: Primary coenzyme Q(10) (CoQ(10)) deficiency is rare.
- reference: PMID:25216398
  title: A Gly-zipper motif mediates homodimerization of the transmembrane domain of the mitochondrial kinase ADCK3.
  found_in:
  - Autosomal_Recessive_Ataxia_Due_to_Ubiquinone_Deficiency-deep-research-openscientist.md
  findings:
  - statement: '2014 Oct 8;136(40):14068-77. doi: 10.1021/ja505017f.'
    supporting_text: '2014 Oct 8;136(40):14068-77. doi: 10.1021/ja505017f.'
- reference: PMID:25498144
  title: Mitochondrial ADCK3 employs an atypical protein kinase-like fold to enable coenzyme Q biosynthesis.
  found_in:
  - Autosomal_Recessive_Ataxia_Due_to_Ubiquinone_Deficiency-deep-research-openscientist.md
  findings:
  - statement: '2015 Jan 8;57(1):83-94. doi: 10.1016/j.molcel.2014.11.002.'
    supporting_text: '2015 Jan 8;57(1):83-94. doi: 10.1016/j.molcel.2014.11.002.'
- reference: PMID:26818466
  title: Cerebellar ataxia and severe muscle CoQ10 deficiency in a patient with a novel mutation in ADCK3.
  found_in:
  - Autosomal_Recessive_Ataxia_Due_to_Ubiquinone_Deficiency-deep-research-openscientist.md
  findings:
  - statement: '2016 Aug;90(2):156-60. doi: 10.1111/cge.12742.'
    supporting_text: '2016 Aug;90(2):156-60. doi: 10.1111/cge.12742.'
- reference: PMID:26866375
  title: AarF Domain Containing Kinase 3 (ADCK3) Mutant Cells Display Signs of Oxidative Stress, Defects in Mitochondrial Homeostasis and Lysosomal Accumulation.
  found_in:
  - Autosomal_Recessive_Ataxia_Due_to_Ubiquinone_Deficiency-deep-research-openscientist.md
  findings:
  - statement: '2016 Feb 11;11(2):e0148213. doi: 10.1371/journal.pone.0148213. eCollection 2016.'
    supporting_text: '2016 Feb 11;11(2):e0148213. doi: 10.1371/journal.pone.0148213. eCollection 2016.'
- reference: PMID:27106809
  title: 'ADCK3 mutations with epilepsy, stroke-like episodes and ataxia: a POLG mimic?'
  found_in:
  - Autosomal_Recessive_Ataxia_Due_to_Ubiquinone_Deficiency-deep-research-openscientist.md
  findings:
  - statement: '2016 Jul;23(7):1188-94. doi: 10.1111/ene.13003.'
    supporting_text: '2016 Jul;23(7):1188-94. doi: 10.1111/ene.13003.'
- reference: PMID:27499294
  title: Cerebellar Ataxia and Coenzyme Q Deficiency through Loss of Unorthodox Kinase Activity.
  found_in:
  - Autosomal_Recessive_Ataxia_Due_to_Ubiquinone_Deficiency-deep-research-openscientist.md
  findings:
  - statement: '2016 Aug 18;63(4):608-620. doi: 10.1016/j.molcel.2016.06.030.'
    supporting_text: '2016 Aug 18;63(4):608-620. doi: 10.1016/j.molcel.2016.06.030.'
- reference: PMID:29194833
  title: Mutations in COQ8B (ADCK4) found in patients with steroid-resistant nephrotic syndrome alter COQ8B function.
  found_in:
  - Autosomal_Recessive_Ataxia_Due_to_Ubiquinone_Deficiency-deep-research-openscientist.md
  findings:
  - statement: '2018 Mar;39(3):406-414. doi: 10.1002/humu.23376.'
    supporting_text: '2018 Mar;39(3):406-414. doi: 10.1002/humu.23376.'
- reference: PMID:30682496
  title: 'Primary coenzyme Q10 Deficiency-6 (COQ10D6): Two siblings with variable expressivity of the renal phenotype.'
  found_in:
  - Autosomal_Recessive_Ataxia_Due_to_Ubiquinone_Deficiency-deep-research-openscientist.md
  findings:
  - statement: '2020 Jan;63(1):103621. doi: 10.1016/j.ejmg.2019.01.011.'
    supporting_text: '2020 Jan;63(1):103621. doi: 10.1016/j.ejmg.2019.01.011.'
- reference: PMID:31621627
  title: 'Dystonia-Ataxia with early handwriting deterioration in COQ8A mutation carriers: A case series and literature review.'
  found_in:
  - Autosomal_Recessive_Ataxia_Due_to_Ubiquinone_Deficiency-deep-research-openscientist.md
  findings:
  - statement: '2019 Nov;68:8-16. doi: 10.1016/j.parkreldis.2019.09.015.'
    supporting_text: '2019 Nov;68:8-16. doi: 10.1016/j.parkreldis.2019.09.015.'
- reference: PMID:32743982
  title: Primary coenzyme Q10 deficiency due to COQ8A gene mutations.
  found_in:
  - Autosomal_Recessive_Ataxia_Due_to_Ubiquinone_Deficiency-deep-research-openscientist.md
  findings:
  - statement: Primary deficiency of coenzyme Q10 deficiency-4 (COQ10D4) is an autosomal recessive cerebellar ataxia with mitochondrial respiratory chain disfunction.
    supporting_text: Primary deficiency of coenzyme Q10 deficiency-4 (COQ10D4) is an autosomal recessive cerebellar ataxia with mitochondrial respiratory chain disfunction.
- reference: PMID:32830305
  title: "Familial writer's cramp: a clinical clue for inherited coenzyme Q(10) deficiency."
  found_in:
  - Autosomal_Recessive_Ataxia_Due_to_Ubiquinone_Deficiency-deep-research-openscientist.md
  findings:
  - statement: '2021 Mar;22(1):81-86. doi: 10.1007/s10048-020-00624-3.'
    supporting_text: '2021 Mar;22(1):81-86. doi: 10.1007/s10048-020-00624-3.'
- reference: PMID:33622667
  title: 'Photoparoxysmal response in ADCK3 autosomal recessive ataxia: a case report and literature review.'
  found_in:
  - Autosomal_Recessive_Ataxia_Due_to_Ubiquinone_Deficiency-deep-research-openscientist.md
  findings:
  - statement: '2021 Feb 1;23(1):153-160. doi: 10.1684/epd.2021.1243.'
    supporting_text: '2021 Feb 1;23(1):153-160. doi: 10.1684/epd.2021.1243.'
- reference: PMID:35275351
  title: Epilepsia Partialis Continua a Clinical Feature of a Missense Variant in the ADCK3 Gene and Poor Response to Therapy.
  found_in:
  - Autosomal_Recessive_Ataxia_Due_to_Ubiquinone_Deficiency-deep-research-openscientist.md
  findings:
  - statement: '2022 May;72(5):1125-1132. doi: 10.1007/s12031-022-01993-0.'
    supporting_text: '2022 May;72(5):1125-1132. doi: 10.1007/s12031-022-01993-0.'
- reference: PMID:35642996
  title: The cerebellar bioenergetic state predicts treatment response in COQ8A-related ataxia.
  found_in:
  - Autosomal_Recessive_Ataxia_Due_to_Ubiquinone_Deficiency-deep-research-openscientist.md
  findings:
  - statement: '2022 Jun;99:91-95. doi: 10.1016/j.parkreldis.2022.05.008.'
    supporting_text: '2022 Jun;99:91-95. doi: 10.1016/j.parkreldis.2022.05.008.'
- reference: PMID:37476682
  title: 'Adolescence Onset Primary Coenzyme Q10 Deficiency With Rare CoQ8A Gene Mutation: A Case Report and Review of Literature.'
  found_in:
  - Autosomal_Recessive_Ataxia_Due_to_Ubiquinone_Deficiency-deep-research-openscientist.md
  findings:
  - statement: Primary deficiency of coenzyme Q10 deficiency-4 (CoQ10D4) is a heterogeneous disorder affecting different age groups.
    supporting_text: Primary deficiency of coenzyme Q10 deficiency-4 (CoQ10D4) is a heterogeneous disorder affecting different age groups.
- reference: PMID:37529414
  title: 'Autosomal Recessive Spinocerebellar Ataxia Type 9 With a Response to Phosphate Repletion: A Case Report.'
  found_in:
  - Autosomal_Recessive_Ataxia_Due_to_Ubiquinone_Deficiency-deep-research-openscientist.md
  findings:
  - statement: '2023 May 9;9(3):e200070. doi: 10.1212/NXG.0000000000200070. eCollection 2023 Jun.'
    supporting_text: '2023 May 9;9(3):e200070. doi: 10.1212/NXG.0000000000200070. eCollection 2023 Jun.'
- reference: PMID:38429489
  title: 'Mitochondrial Dysfunction due to Novel COQ8A Variation with Poor Response to CoQ10 Treatment: A Comprehensive Study and Review of Literatures.'
  found_in:
  - Autosomal_Recessive_Ataxia_Due_to_Ubiquinone_Deficiency-deep-research-openscientist.md
  findings:
  - statement: '2024 Oct;23(5):1824-1838. doi: 10.1007/s12311-024-01671-4.'
    supporting_text: '2024 Oct;23(5):1824-1838. doi: 10.1007/s12311-024-01671-4.'
- reference: PMID:40645015
  title: Generation of an induced pluripotent stem cell (iPSC) line (XMUi001-A) derived from a patient harboring homozygous mutations c.370G > A (p.Gly124Ser) in the COQ4 gene.
  found_in:
  - Autosomal_Recessive_Ataxia_Due_to_Ubiquinone_Deficiency-deep-research-openscientist.md
  findings:
  - statement: '2025 Sep;87:103764. doi: 10.1016/j.scr.2025.103764.'
    supporting_text: '2025 Sep;87:103764. doi: 10.1016/j.scr.2025.103764.'
- reference: PMID:41769026
  title: 'Coenzyme Q10 Supplementation in a Child with Biallelic COQ8A Variants: A Case Report.'
  found_in:
  - Autosomal_Recessive_Ataxia_Due_to_Ubiquinone_Deficiency-deep-research-openscientist.md
  findings:
  - statement: '2026 Jan 16;18(1):121-127. doi: 10.1159/000550495. eCollection 2026 Jan-Dec.'
    supporting_text: '2026 Jan 16;18(1):121-127. doi: 10.1159/000550495. eCollection 2026 Jan-Dec.'
- reference: PMID:42036720
  title: The Drp1-CoQ10-Coa6-ETC axis represents a therapeutic potential for working memory impairment caused by neuronal mitochondrial dysfunction.
  found_in:
  - Autosomal_Recessive_Ataxia_Due_to_Ubiquinone_Deficiency-deep-research-openscientist.md
  findings:
  - statement: Coenzyme Q10 (CoQ10) is a key mitochondrial electron carrier and a widely used dietary supplement with potential neurological benefits.
    supporting_text: Coenzyme Q10 (CoQ10) is a key mitochondrial electron carrier and a widely used dietary supplement with potential neurological benefits.
- reference: PMID:30968303
  title: Primary Coenzyme Q deficiency Due to Novel ADCK3 Variants, Studies in Fibroblasts and Review of Literature.
  found_in:
  - Autosomal_Recessive_Ataxia_Due_to_Ubiquinone_Deficiency-deep-research-openscientist.md
  findings: []
- reference: PMID:35139868
  title: Loss of Drosophila Coq8 results in impaired survival, locomotor deficits and photoreceptor degeneration.
  found_in:
  - Autosomal_Recessive_Ataxia_Due_to_Ubiquinone_Deficiency-deep-research-openscientist.md
  findings: []
📚

References & Deep Research

References

30
DOI:10.1002/ana.25751
Clinico‐Genetic, Imaging and Molecular Delineation of <scp><i>COQ8A</i></scp>‐Ataxia: A Multicenter Study of 59 Patients
1 finding
Clinico‐Genetic, Imaging and Molecular Delineation of <scp><i>COQ8A</i></scp>‐Ataxia: A Multicenter Study of 59 Patients
"To foster trial‐readiness of coenzyme Q8A (COQ8A)‐ataxia, we map the clinicogenetic, molecular, and neuroimaging spectrum of COQ8A‐ataxia in a large worldwide cohort, and provide first progression data, including treatment response to coenzyme Q10 (CoQ10).MethodsCross‐modal analysis of a..."
DOI:10.3390/metabo12100955
COQ8A-Ataxia as a Manifestation of Primary Coenzyme Q Deficiency
1 finding
COQ8A-ataxia is a mitochondrial disease in which a defect in coenzyme Q10 synthesis leads to dysfunction of the respiratory chain.
"COQ8A-ataxia is a mitochondrial disease in which a defect in coenzyme Q10 synthesis leads to dysfunction of the respiratory chain."
DOI:10.3390/jcm13082391
Primary Coenzyme Q10 Deficiency-Related Ataxias
1 finding
Cerebellar ataxia is a neurological syndrome characterized by the imbalance (e.g., truncal ataxia, gait ataxia) and incoordination of limbs while executing a task (dysmetria), caused by the dysfunction of the cerebellum or its connections.
"Cerebellar ataxia is a neurological syndrome characterized by the imbalance (e.g., truncal ataxia, gait ataxia) and incoordination of limbs while executing a task (dysmetria), caused by the dysfunction of the cerebellum or its connections."
DOI:10.1007/s11064-019-02786-5
Primary Coenzyme Q deficiency Due to Novel ADCK3 Variants, Studies in Fibroblasts and Review of Literature
1 finding
Primary Coenzyme Q deficiency Due to Novel ADCK3 Variants, Studies in Fibroblasts and Review of Literature
"Primary Coenzyme Q deficiency Due to Novel ADCK3 Variants, Studies in Fibroblasts and Review of Literature"
DOI:10.1186/s13041-022-00900-3
Loss of Drosophila Coq8 results in impaired survival, locomotor deficits and photoreceptor degeneration
1 finding
Coenzyme Q8A encodes the homologue of yeast coq8, an ATPase that is required for the biosynthesis of Coenzyme Q10, an essential component of the electron transport chain.
"Coenzyme Q8A encodes the homologue of yeast coq8, an ATPase that is required for the biosynthesis of Coenzyme Q10, an essential component of the electron transport chain."
DOI:10.1212/nxg.0000000000200209
Clinical Features, Biochemistry, Imaging, and Treatment Response in a Single-Center Cohort With Coenzyme Q <sub>10</sub> Biosynthesis Disorders
1 finding
Clinical Features, Biochemistry, Imaging, and Treatment Response in a Single-Center Cohort With Coenzyme Q <sub>10</sub> Biosynthesis Disorders
"Clinical Features, Biochemistry, Imaging, and Treatment Response in a Single-Center Cohort With Coenzyme Q <sub>10</sub> Biosynthesis Disorders"
PMID:10760477
Genetic evidence for a multi-subunit complex in the O-methyltransferase steps of coenzyme Q biosynthesis.
1 finding
2000 Apr 12;1484(2-3):287-97. doi: 10.1016/s1388-1981(00)00019-6.
"2000 Apr 12;1484(2-3):287-97. doi: 10.1016/s1388-1981(00)00019-6."
PMID:15710863
Isolated mitochondrial myopathy associated with muscle coenzyme Q10 deficiency.
1 finding
Primary coenzyme Q(10) (CoQ(10)) deficiency is rare.
"Primary coenzyme Q(10) (CoQ(10)) deficiency is rare."
PMID:25216398
A Gly-zipper motif mediates homodimerization of the transmembrane domain of the mitochondrial kinase ADCK3.
1 finding
2014 Oct 8;136(40):14068-77. doi: 10.1021/ja505017f.
"2014 Oct 8;136(40):14068-77. doi: 10.1021/ja505017f."
PMID:25498144
Mitochondrial ADCK3 employs an atypical protein kinase-like fold to enable coenzyme Q biosynthesis.
1 finding
2015 Jan 8;57(1):83-94. doi: 10.1016/j.molcel.2014.11.002.
"2015 Jan 8;57(1):83-94. doi: 10.1016/j.molcel.2014.11.002."
PMID:26818466
Cerebellar ataxia and severe muscle CoQ10 deficiency in a patient with a novel mutation in ADCK3.
1 finding
2016 Aug;90(2):156-60. doi: 10.1111/cge.12742.
"2016 Aug;90(2):156-60. doi: 10.1111/cge.12742."
PMID:26866375
AarF Domain Containing Kinase 3 (ADCK3) Mutant Cells Display Signs of Oxidative Stress, Defects in Mitochondrial Homeostasis and Lysosomal Accumulation.
1 finding
2016 Feb 11;11(2):e0148213. doi: 10.1371/journal.pone.0148213. eCollection 2016.
"2016 Feb 11;11(2):e0148213. doi: 10.1371/journal.pone.0148213. eCollection 2016."
PMID:27106809
ADCK3 mutations with epilepsy, stroke-like episodes and ataxia: a POLG mimic?
1 finding
2016 Jul;23(7):1188-94. doi: 10.1111/ene.13003.
"2016 Jul;23(7):1188-94. doi: 10.1111/ene.13003."
PMID:27499294
Cerebellar Ataxia and Coenzyme Q Deficiency through Loss of Unorthodox Kinase Activity.
1 finding
2016 Aug 18;63(4):608-620. doi: 10.1016/j.molcel.2016.06.030.
"2016 Aug 18;63(4):608-620. doi: 10.1016/j.molcel.2016.06.030."
PMID:29194833
Mutations in COQ8B (ADCK4) found in patients with steroid-resistant nephrotic syndrome alter COQ8B function.
1 finding
2018 Mar;39(3):406-414. doi: 10.1002/humu.23376.
"2018 Mar;39(3):406-414. doi: 10.1002/humu.23376."
PMID:30682496
Primary coenzyme Q10 Deficiency-6 (COQ10D6): Two siblings with variable expressivity of the renal phenotype.
1 finding
2020 Jan;63(1):103621. doi: 10.1016/j.ejmg.2019.01.011.
"2020 Jan;63(1):103621. doi: 10.1016/j.ejmg.2019.01.011."
PMID:31621627
Dystonia-Ataxia with early handwriting deterioration in COQ8A mutation carriers: A case series and literature review.
1 finding
2019 Nov;68:8-16. doi: 10.1016/j.parkreldis.2019.09.015.
"2019 Nov;68:8-16. doi: 10.1016/j.parkreldis.2019.09.015."
PMID:32743982
Primary coenzyme Q10 deficiency due to COQ8A gene mutations.
1 finding
Primary deficiency of coenzyme Q10 deficiency-4 (COQ10D4) is an autosomal recessive cerebellar ataxia with mitochondrial respiratory chain disfunction.
"Primary deficiency of coenzyme Q10 deficiency-4 (COQ10D4) is an autosomal recessive cerebellar ataxia with mitochondrial respiratory chain disfunction."
PMID:32830305
Familial writer's cramp: a clinical clue for inherited coenzyme Q(10) deficiency.
1 finding
2021 Mar;22(1):81-86. doi: 10.1007/s10048-020-00624-3.
"2021 Mar;22(1):81-86. doi: 10.1007/s10048-020-00624-3."
PMID:33622667
Photoparoxysmal response in ADCK3 autosomal recessive ataxia: a case report and literature review.
1 finding
2021 Feb 1;23(1):153-160. doi: 10.1684/epd.2021.1243.
"2021 Feb 1;23(1):153-160. doi: 10.1684/epd.2021.1243."
PMID:35275351
Epilepsia Partialis Continua a Clinical Feature of a Missense Variant in the ADCK3 Gene and Poor Response to Therapy.
1 finding
2022 May;72(5):1125-1132. doi: 10.1007/s12031-022-01993-0.
"2022 May;72(5):1125-1132. doi: 10.1007/s12031-022-01993-0."
PMID:35642996
The cerebellar bioenergetic state predicts treatment response in COQ8A-related ataxia.
1 finding
2022 Jun;99:91-95. doi: 10.1016/j.parkreldis.2022.05.008.
"2022 Jun;99:91-95. doi: 10.1016/j.parkreldis.2022.05.008."
PMID:37476682
Adolescence Onset Primary Coenzyme Q10 Deficiency With Rare CoQ8A Gene Mutation: A Case Report and Review of Literature.
1 finding
Primary deficiency of coenzyme Q10 deficiency-4 (CoQ10D4) is a heterogeneous disorder affecting different age groups.
"Primary deficiency of coenzyme Q10 deficiency-4 (CoQ10D4) is a heterogeneous disorder affecting different age groups."
PMID:37529414
Autosomal Recessive Spinocerebellar Ataxia Type 9 With a Response to Phosphate Repletion: A Case Report.
1 finding
2023 May 9;9(3):e200070. doi: 10.1212/NXG.0000000000200070. eCollection 2023 Jun.
"2023 May 9;9(3):e200070. doi: 10.1212/NXG.0000000000200070. eCollection 2023 Jun."
PMID:38429489
Mitochondrial Dysfunction due to Novel COQ8A Variation with Poor Response to CoQ10 Treatment: A Comprehensive Study and Review of Literatures.
1 finding
2024 Oct;23(5):1824-1838. doi: 10.1007/s12311-024-01671-4.
"2024 Oct;23(5):1824-1838. doi: 10.1007/s12311-024-01671-4."
PMID:40645015
Generation of an induced pluripotent stem cell (iPSC) line (XMUi001-A) derived from a patient harboring homozygous mutations c.370G > A (p.Gly124Ser) in the COQ4 gene.
1 finding
2025 Sep;87:103764. doi: 10.1016/j.scr.2025.103764.
"2025 Sep;87:103764. doi: 10.1016/j.scr.2025.103764."
PMID:41769026
Coenzyme Q10 Supplementation in a Child with Biallelic COQ8A Variants: A Case Report.
1 finding
2026 Jan 16;18(1):121-127. doi: 10.1159/000550495. eCollection 2026 Jan-Dec.
"2026 Jan 16;18(1):121-127. doi: 10.1159/000550495. eCollection 2026 Jan-Dec."
PMID:42036720
The Drp1-CoQ10-Coa6-ETC axis represents a therapeutic potential for working memory impairment caused by neuronal mitochondrial dysfunction.
1 finding
Coenzyme Q10 (CoQ10) is a key mitochondrial electron carrier and a widely used dietary supplement with potential neurological benefits.
"Coenzyme Q10 (CoQ10) is a key mitochondrial electron carrier and a widely used dietary supplement with potential neurological benefits."
PMID:30968303
Primary Coenzyme Q deficiency Due to Novel ADCK3 Variants, Studies in Fibroblasts and Review of Literature.
No top-level findings curated for this source.
PMID:35139868
Loss of Drosophila Coq8 results in impaired survival, locomotor deficits and photoreceptor degeneration.
No top-level findings curated for this source.

Deep Research

2
Falcon ▸
Disease Characteristics Research Template
Edison Scientific Literature 15 citations 2026-04-23T18:44:18.220317

Question: You are an expert researcher providing comprehensive, well-cited information.

Provide detailed information focusing on: 1. Key concepts and definitions with current understanding 2. Recent developments and latest research (prioritize 2023-2024 sources) 3. Current applications and real-world implementations 4. Expert opinions and analysis from authoritative sources 5. Relevant statistics and data from recent studies

Format as a comprehensive research report with proper citations. Include URLs and publication dates where available. Always prioritize recent, authoritative sources and provide specific citations for all major claims.

Disease Characteristics Research Template

Target Disease

  • Disease Name: Autosomal Recessive Ataxia Due to Ubiquinone Deficiency
  • MONDO ID: (if available)
  • Category: Neurological Disorder

Research Objectives

Please provide a comprehensive research report on Autosomal Recessive Ataxia Due to Ubiquinone Deficiency covering all of the disease characteristics listed below. This report will be used to populate a disease knowledge base entry. Be thorough and cite primary literature (PMID preferred) for all claims.

For each section, suggested databases/resources are listed. These are the first places you should search for information on each topic.

1. Disease Information

Search first: OMIM, Orphanet, ICD-10/ICD-11, MeSH, PubMed

  • What is the disease? Provide a concise overview.
  • What are the key identifiers? (OMIM, Orphanet, ICD-10/ICD-11, MeSH, Mondo)
  • What are the common synonyms and alternative names?
  • Is the information derived from individual patients (e.g., EHR) or aggregated disease-level resources?

2. Etiology

  • Disease Causal Factors: What are the primary causes? (genetic, environmental, infectious, mechanistic)
  • Risk Factors:

    Search first: PubMed, Cochrane Library, UpToDate, clinical guidelines, ClinVar, ClinGen, GWAS Catalog, PheGenI, CTD, CDC, WHO, epidemiological databases

  • Genetic risk factors (causal variants, susceptibility loci, modifier genes)
  • Environmental risk factors (toxins, lifestyle, occupational exposures, age, sex, family history)
  • Protective Factors:

    Search first: PubMed, Cochrane Library, clinical trial databases, GWAS Catalog, gnomAD, WHO, CDC, nutrition databases

  • Genetic protective factors (protective variants, modifier alleles)
  • Environmental protective factors (diet, lifestyle, exposures that reduce risk)
  • Gene-Environment Interactions: How do genetic and environmental factors interact to influence disease?

    Search first: CTD, PubMed, PheGenI, GxE databases

3. Phenotypes

Search first: HPO (Human Phenotype Ontology), OMIM, Orphanet, PubMed, clinicaltrials.gov, MedDRA, SNOMED CT, DECIPHER, LOINC

For each phenotype, provide: - Phenotype type: symptoms, clinical signs, physical manifestations, behavioral changes, or laboratory abnormalities

For symptoms/signs: HPO, OMIM, Orphanet, PubMed For behavioral changes: HPO, DSM, RDoC (Research Domain Criteria), PubMed For laboratory abnormalities: LOINC, SNOMED CT, LabTests Online, PubMed - Phenotype characteristics: Search first: OMIM, Orphanet, HPO, PubMed - Age of symptom onset (neonatal, childhood, adult-onset, late-onset) - Symptom severity (mild, moderate, severe, variable) - Symptom progression (stable, progressive, episodic, fluctuating) - Frequency among affected individuals (percentage or qualitative) - Quality of life impact: Effects on daily functioning and well-being (per-phenotype when possible) Search first: EQ-5D database, SF-36, WHO QOL databases, PubMed - Suggest HPO (Human Phenotype Ontology) terms for each phenotype

4. Genetic/Molecular Information

  • Causal Genes: Gene mutations or chromosomal abnormalities responsible for disease (gene symbols, OMIM IDs)

    Search first: OMIM, ClinVar, HGMD, Ensembl, NCBI Gene

  • Pathogenic Variants:
  • Affected genes (gene symbols, HGNC IDs) > Search first: OMIM, NCBI Gene, Ensembl, HGNC, UniProt, GeneCards
  • Variant classification (pathogenic, likely pathogenic, VUS per ACMG/AMP guidelines) > Search first: ClinVar, ClinGen, ACMG/AMP guidelines, VarSome
  • Variant type/class (missense, frameshift, nonsense, splice-site, structural)
  • Allele frequency in population databases > Search first: gnomAD, 1000 Genomes, ExAC, TOPMed, dbSNP
  • Somatic vs germline origin > Search first: COSMIC (somatic), ClinVar, ICGC, TCGA
  • Functional consequences (loss of function, gain of function, dominant negative)
  • Modifier Genes: Genes that modify disease severity or expression
  • Epigenetic Information: DNA methylation, histone modifications, chromatin changes affecting disease

    Search first: ENCODE, Roadmap Epigenomics, MethBase, DiseaseMeth

  • Chromosomal Abnormalities: Large-scale genetic changes (aneuploidy, translocations, inversions)

    Search first: DECIPHER, ClinVar, ECARUCA, UCSC Genome Browser

5. Environmental Information

  • Environmental Factors: Non-genetic contributing factors (toxins, radiation, pollution, occupational exposure)

    Search first: CTD (Comparative Toxicogenomics Database), TOXNET, PubMed, EPA databases

  • Lifestyle Factors: Behavioral factors (smoking, diet, exercise, alcohol consumption)

    Search first: CDC databases, WHO, PubMed, NHANES

  • Infectious Agents: If applicable, pathogens causing or triggering disease (bacteria, viruses, fungi, parasites)

    Search first: NCBI Taxonomy, ViPR, BV-BRC, MicrobeDB, GIDEON

6. Mechanism / Pathophysiology

  • Molecular Pathways: Specific signaling cascades or biochemical pathways involved (Wnt, MAPK, mTOR, PI3K-AKT, etc.)

    Search first: KEGG, Reactome, WikiPathways, PathBank, BioCyc

  • Cellular Processes: Cell-level mechanisms (apoptosis, autophagy, cell cycle dysregulation, inflammation, etc.)

    Search first: Gene Ontology (GO), Reactome, KEGG, PubMed

  • Protein Dysfunction: How protein structure or function is altered (misfolding, aggregation, loss of function, gain of function)

    Search first: UniProt, PDB (Protein Data Bank), InterPro, Pfam, AlphaFold

  • Metabolic Changes: Alterations in metabolic processes (energy metabolism, lipid metabolism, amino acid metabolism)

    Search first: KEGG, BioCyc, HMDB (Human Metabolome Database), BRENDA

  • Immune System Involvement: Role of immune response (autoimmunity, immunodeficiency, chronic inflammation)

    Search first: ImmPort, Immunome Database, IEDB, Gene Ontology

  • Tissue Damage Mechanisms: How tissues/ are injured (oxidative stress, ischemia, fibrosis, necrosis)

    Search first: PubMed, Gene Ontology, Reactome

  • Biochemical Abnormalities: Specific molecular defects (enzyme deficiencies, receptor dysfunction, ion channel defects)

    Search first: BRENDA, UniProt, KEGG, OMIM, PubMed

  • Epigenetic Changes: DNA methylation, histone modifications affecting gene expression in disease

    Search first: ENCODE, Roadmap Epigenomics, MethBase, DiseaseMeth

  • Molecular Profiling (if available):
  • Transcriptomics/gene expression changes > Search first: GEO (Gene Expression Omnibus), ArrayExpress, GTEx, Human Cell Atlas, SRA
  • Proteomics findings > Search first: PRIDE, ProteomeXchange, Human Protein Atlas, STRING, BioGRID
  • Metabolomics signatures > Search first: MetaboLights, Metabolomics Workbench, HMDB, METLIN
  • Lipidomics alterations > Search first: LIPID MAPS, SwissLipids, LipidHome, Metabolomics Workbench
  • Genomic structural features > Search first: UCSC Genome Browser, Ensembl, NCBI, dbVar, DGV
  • Advanced Technologies (if applicable):
  • Single-cell analysis findings (cell-type specific mechanisms, cellular heterogeneity) > Search first: Human Cell Atlas, Single Cell Portal, GEO, CELLxGENE
  • Spatial transcriptomics findings > Search first: GEO, Spatial Research, Vizgen, 10x Genomics data
  • Multi-omics integration results > Search first: TCGA, ICGC, cBioPortal, LinkedOmics, PubMed
  • Functional genomics screens (CRISPR, RNAi) > Search first: DepMap, GenomeRNAi, PubMed, BioGRID ORCS

For each mechanism, describe: - The causal chain from initial trigger to clinical manifestation - Which mechanisms are upstream vs downstream - What cell types and biological processes are involved - Suggest GO terms for biological processes and CL terms for cell types

7. Anatomical Structures Affected

  • Organ Level:
  • Primary organs directly affected
  • Secondary organ involvement (complications, secondary effects)
  • Body systems involved (cardiovascular, nervous, digestive, respiratory, endocrine, etc.)

    Search first: Uberon, FMA (Foundational Model of Anatomy), OMIM, HPO, ICD-11, MeSH, SNOMED CT

  • Tissue and Cell Level:
  • Specific tissue types affected (epithelial, connective, muscle, nervous)
  • Specific cell populations targeted (with Cell Ontology terms)

    Search first: Uberon, Human Protein Atlas, Cell Ontology, Human Cell Atlas, CellMarker, PanglaoDB

  • Subcellular Level:
  • Cellular compartments involved (mitochondria, nucleus, ER, lysosomes) (with GO Cellular Component terms)

    Search first: Gene Ontology (Cellular Component), UniProt, Human Protein Atlas

  • Localization:
  • Specific anatomical sites (with UBERON terms) > Search first: FMA, Uberon, NeuroNames (for brain), SNOMED CT
  • Lateralization (unilateral, bilateral, asymmetric) > Search first: HPO, clinical literature, imaging databases

8. Temporal Development

  • Onset:
  • Typical age of onset (congenital, pediatric, adult, geriatric)
  • Onset pattern (acute, subacute, chronic, insidious)

    Search first: OMIM, Orphanet, HPO, PubMed

  • Progression:
  • Disease stages (early, intermediate, advanced, end-stage) > Search first: Cancer Staging Manual (AJCC), WHO classifications, PubMed
  • Progression rate (rapid, slow, variable)
  • Disease course pattern (episodic, relapsing-remitting, progressive, stable)
  • Disease duration (self-limited, chronic lifelong)

    Search first: Disease registries, longitudinal cohort databases, natural history studies, PubMed, Orphanet, OMIM

  • Patterns:
  • Remission patterns (spontaneous, treatment-induced) > Search first: Clinical trial databases, disease registries, PubMed
  • Critical periods (time windows of vulnerability or opportunity for intervention) > Search first: PubMed, developmental biology databases, clinical guidelines

9. Inheritance and Population

  • Epidemiology:
  • Prevalence (cases per 100,000 at given time)
  • Incidence (new cases per 100,000 per year)

    Search first: Orphanet, CDC, WHO, GBD (Global Burden of Disease), national registries, SEER, disease registries

  • For Genetic Etiology:
  • Inheritance pattern (AD, AR, X-linked, mitochondrial, multifactorial, polygenic) > Search first: OMIM, Orphanet, ClinVar, GTR (Genetic Testing Registry)
  • Penetrance (complete, incomplete, age-dependent) > Search first: ClinVar, OMIM, PubMed, ClinGen
  • Expressivity (variable, consistent) > Search first: OMIM, ClinVar, PubMed
  • Genetic anticipation (increasing severity in successive generations) > Search first: OMIM, PubMed (especially for repeat expansion disorders)
  • Germline mosaicism > Search first: ClinVar, OMIM, genetic counseling literature, PubMed
  • Founder effects (population-specific mutations) > Search first: gnomAD, population genetics databases, PubMed
  • Consanguinity role > Search first: OMIM, population studies, genetic counseling resources
  • Carrier frequency > Search first: gnomAD, carrier screening databases, GeneReviews, GTR
  • Population Demographics:
  • Affected populations (ethnic or demographic groups with higher prevalence) > Search first: gnomAD, 1000 Genomes, PAGE Study, PubMed, population registries
  • Geographic distribution (endemic areas, regional variation) > Search first: WHO, CDC, GBD, Orphanet, geographic epidemiology databases
  • Geographic distribution of specific variants
  • Sex ratio (male:female) > Search first: Disease registries, OMIM, PubMed, epidemiological databases
  • Age distribution of affected individuals > Search first: CDC, disease registries, SEER, Orphanet

10. Diagnostics

  • Clinical Tests:
  • Laboratory tests (blood, urine, tissue chemistry, specific enzyme assays) > Search first: LOINC, LabTests Online, PubMed
  • Biomarkers (proteins, metabolites, genetic markers, circulating biomarkers) > Search first: FDA Biomarker List, BEST (Biomarkers, EndpointS, and other Tools), PubMed
  • Imaging studies (X-ray, CT, MRI, PET, ultrasound) > Search first: RadLex, DICOM, Radiopaedia, imaging databases
  • Functional tests (pulmonary function, cardiac stress tests) > Search first: LOINC, clinical guidelines, PubMed
  • Electrophysiology (EEG, EMG, ECG, nerve conduction studies) > Search first: LOINC, clinical neurophysiology databases, PubMed
  • Biopsy findings (histopathology, immunohistochemistry) > Search first: SNOMED CT, College of American Pathologists resources, PubMed
  • Pathology findings (microscopic examination) > Search first: SNOMED CT, Digital Pathology databases, PubMed
  • Genetic Testing:

    Search first: GTR (Genetic Testing Registry), GeneReviews, ClinGen

  • Overview of recommended genetic testing approach
  • Whole genome sequencing (WGS) utility > Search first: GTR, ClinVar, GEL (Genomics England), gnomAD
  • Whole exome sequencing (WES) utility > Search first: GTR, ClinVar, OMIM, GeneMatcher
  • Gene panels (which panels, which genes) > Search first: GTR, ClinVar, laboratory-specific databases
  • Single gene testing > Search first: GTR, ClinVar, OMIM, GeneReviews
  • Chromosomal microarray (CMA) > Search first: DECIPHER, ClinVar, dbVar, ECARUCA
  • Karyotyping > Search first: Chromosome Abnormality Database, ClinVar, cytogenetics resources
  • FISH > Search first: ClinVar, cytogenetics databases, PubMed
  • Mitochondrial DNA testing > Search first: MITOMAP, MSeqDR, ClinVar, GTR
  • Repeat expansion testing > Search first: GTR, ClinVar, repeat expansion databases, PubMed
  • Omics-Based Diagnostics (if applicable):
  • RNA sequencing / transcriptomics > Search first: GEO, ArrayExpress, GTEx, RNA-seq databases
  • Proteomics > Search first: PRIDE, ProteomeXchange, FDA Biomarker database
  • Metabolomics > Search first: MetaboLights, Metabolomics Workbench, HMDB
  • Epigenomics > Search first: GEO, ENCODE, Roadmap Epigenomics, MethBase
  • Liquid biopsy > Search first: COSMIC, ClinVar, liquid biopsy databases, PubMed
  • Clinical Criteria:
  • Standardized diagnostic criteria (DSM, ICD, society guidelines) > Search first: DSM-5, ICD-11, clinical society guidelines, UpToDate
  • Differential diagnosis (other conditions to rule out, with distinguishing features) > Search first: DynaMed, UpToDate, clinical decision support systems
  • Screening:
  • Screening methods for asymptomatic individuals (newborn screening, carrier screening, cascade screening) > Search first: ACMG recommendations, CDC newborn screening, GTR

11. Outcome/Prognosis

  • Survival and Mortality:
  • Survival rate (5-year, 10-year, overall) > Search first: SEER, cancer registries, disease-specific registries, PubMed
  • Life expectancy (with and without treatment if applicable) > Search first: Orphanet, disease registries, actuarial databases, PubMed
  • Mortality rate > Search first: CDC, WHO, GBD, national mortality databases
  • Disease-specific mortality (deaths directly attributable to disease) > Search first: Disease registries, CDC Wonder, GBD, PubMed
  • Morbidity and Function:
  • Morbidity (disease-related disability and health impacts) > Search first: GBD, WHO, disability databases, PubMed
  • Disability outcomes (long-term functional impairments) > Search first: ICF (International Classification of Functioning), disability registries
  • Quality of life measures (EQ-5D, SF-36, PROMIS, disease-specific tools) > Search first: EQ-5D database, SF-36, PROMIS, PubMed
  • Disease Course:
  • Complications (secondary problems: infections, organ failure, etc.) > Search first: ICD codes, disease registries, clinical databases, PubMed
  • Recovery potential (likelihood and extent of recovery, with vs without treatment) > Search first: Natural history studies, rehabilitation databases, PubMed
  • Prediction:
  • Prognostic factors (age, disease severity, biomarkers, treatment response) > Search first: Prognostic models databases, clinical calculators, PubMed
  • Prognostic biomarkers (molecular markers predicting disease course) > Search first: FDA Biomarker database, PubMed, cancer prognostic databases

12. Treatment

  • Pharmacotherapy:
  • Pharmacological treatments (drug names, drug classes, mechanisms of action) > Search first: DrugBank, RxNorm, ATC classification, DailyMed, FDA databases
  • Pharmacogenomics (how genetic variants affect drug metabolism, efficacy, toxicity) > Search first: PharmGKB, CPIC (Clinical Pharmacogenetics), FDA Table of PGx Biomarkers
  • Advanced Therapeutics:
  • Gene therapy (viral vectors, CRISPR, gene replacement, gene editing) > Search first: ClinicalTrials.gov, FDA gene therapy database, ASGCT resources
  • Cell therapy (stem cell transplant, CAR-T, cellular therapeutics) > Search first: ClinicalTrials.gov, FDA cell therapy database, FACT standards
  • RNA-based therapies (ASOs, siRNA, mRNA therapies) > Search first: ClinicalTrials.gov, FDA approvals, PubMed
  • Targeted therapies (treatments directed at specific molecular targets) > Search first: My Cancer Genome, OncoKB, ClinicalTrials.gov, FDA approvals
  • Immunotherapies (checkpoint inhibitors, monoclonal antibodies) > Search first: Cancer Immunotherapy Database, FDA approvals, ClinicalTrials.gov
  • Surgical and Interventional:
  • Surgical interventions (types of surgery, timing, outcomes) > Search first: CPT codes, surgical registries, clinical guidelines, PubMed
  • Supportive and Rehabilitative:
  • Supportive care (symptom management, pain control, nutrition) > Search first: Clinical guidelines, Cochrane Library, PubMed
  • Rehabilitation (physical therapy, occupational therapy, speech therapy) > Search first: Rehabilitation medicine databases, clinical guidelines, PubMed
  • Experimental:
  • Experimental treatments in clinical trials (with NCT identifiers if available) > Search first: ClinicalTrials.gov, EU Clinical Trials Register, WHO ICTRP
  • Treatment Outcomes:
  • Treatment response rates > Search first: Clinical trial databases, FDA reviews, systematic reviews, PubMed
  • Side effects and adverse events > Search first: FDA Adverse Event Reporting System (FAERS), MedWatch, PubMed
  • Treatment Strategy:
  • Treatment algorithms (clinical pathways, decision trees) > Search first: Clinical practice guidelines, NCCN Guidelines, UpToDate
  • Combination therapies > Search first: ClinicalTrials.gov, treatment guidelines, PubMed
  • Personalized medicine approaches (genotype-guided treatment) > Search first: My Cancer Genome, CIViC, PharmGKB, precision medicine databases

For each treatment, suggest MAXO (Medical Action Ontology) terms where applicable.

13. Prevention

  • Prevention Levels:
  • Primary prevention (preventing disease occurrence: vaccination, risk factor modification) > Search first: CDC, WHO, USPSTF recommendations, Cochrane Library
  • Secondary prevention (early detection and treatment: screening programs, early intervention) > Search first: USPSTF, CDC screening guidelines, WHO
  • Tertiary prevention (preventing complications in those with disease) > Search first: Clinical guidelines, disease management protocols, PubMed
  • Immunization: Vaccine strategies (if applicable)

    Search first: CDC vaccine schedules, WHO immunization, FDA vaccine database

  • Screening and Early Detection:
  • Screening programs (population-based: newborn screening, cancer screening) > Search first: CDC screening programs, USPSTF, cancer screening databases
  • Genetic screening (carrier screening, preimplantation genetic diagnosis, prenatal testing) > Search first: ACMG recommendations, ACOG guidelines, GTR
  • Risk stratification (identifying high-risk individuals for targeted prevention) > Search first: Risk prediction models, clinical calculators, PubMed
  • Behavioral Interventions: Lifestyle modifications to reduce risk

    Search first: CDC, WHO, behavioral intervention databases, Cochrane Library

  • Counseling: Genetic counseling (risk assessment, family planning guidance)

    Search first: NSGC resources, ACMG guidelines, GeneReviews

  • Public Health:
  • Public health interventions (sanitation, vector control, health education) > Search first: CDC, WHO, public health databases, PubMed
  • Environmental interventions (reducing environmental risk factors) > Search first: EPA databases, WHO environmental health, PubMed
  • Prophylaxis: Preventive medications or procedures

    Search first: Clinical guidelines, FDA approvals, PubMed

14. Other Species / Natural Disease

  • Taxonomy: Species affected (with NCBI Taxon identifiers)

    Search first: NCBI Taxonomy

  • Breed: Specific breeds affected (with VBO identifiers if applicable)

    Search first: VBO (Vertebrate Breed Ontology)

  • Gene: Orthologous genes in other species (with NCBI Gene IDs)

    Search first: NCBI Gene

  • Natural Disease:
  • Naturally occurring disease in other species (companion animals, wildlife) > Search first: OMIA (Online Mendelian Inheritance in Animals), VetCompass, PubMed
  • Veterinary relevance and importance in animal health > Search first: OMIA, veterinary databases, PubMed
  • Comparative Biology:
  • Comparative pathology (similarities and differences across species) > Search first: OMIA, comparative pathology databases, PubMed
  • Evolutionary conservation of disease mechanisms > Search first: HomoloGene, OrthoMCL, Alliance of Genome Resources
  • Transmission (if applicable):
  • Zoonotic potential > Search first: CDC zoonotic diseases, WHO zoonoses, GIDEON
  • Cross-species susceptibility > Search first: NCBI Taxonomy, veterinary databases, PubMed

15. Model Organisms

  • Model Types:
  • Model organism type (mammalian, invertebrate, cellular, in vitro) > Search first: Alliance of Genome Resources, model organism databases
  • Specific model systems (mouse, rat, zebrafish, Drosophila, C. elegans, yeast, cell lines, organoids, iPSCs) > Search first: MGI, RGD, ZFIN, FlyBase, WormBase, SGD, ATCC, Cellosaurus
  • Induced models (drug treatment, surgical intervention, environmental manipulation) > Search first: MGI, model organism databases, PubMed
  • Genetic Models:
  • Types available (knockout, knock-in, transgenic, conditional, humanized) > Search first: MGI, IMPC, KOMP, EuMMCR, IMSR
  • Model Characteristics:
  • Phenotype recapitulation (how well model reproduces human disease features) > Search first: Model organism databases, comparative studies, PubMed
  • Model limitations (aspects of human disease not captured) > Search first: Model organism databases, PubMed, review articles
  • Applications:
  • Research applications (what aspects of disease can be studied) > Search first: Model organism databases, PubMed
  • Resources:
  • Model databases > Search first: MGI, RGD, ZFIN, FlyBase, WormBase, IMSR, EMMA, MMRRC

Citation Requirements

  • Cite primary literature (PMID preferred) for all mechanistic and clinical claims
  • Prioritize recent reviews and landmark papers
  • Include direct quotes from abstracts where possible to support key statements
  • Distinguish evidence source types: human clinical, model organism, in vitro, computational

Output Format

Structure your response as a comprehensive narrative organized by the sections above. For each section, provide: - Factual content with specific details (numbers, percentages, gene names, variant nomenclature) - Ontology term suggestions (HPO, GO, CL, UBERON, CHEBI, MAXO, MONDO) where applicable - Evidence citations with PMIDs - Direct quotes from abstracts to support key claims - Clear indication when information is not available or not applicable for this disease

This report will be used to populate a disease knowledge base entry with: - Pathophysiology descriptions with causal chains - Gene/protein annotations (HGNC, GO terms) - Phenotype associations (HP terms) with frequencies - Cell type involvement (CL terms) - Anatomical locations (UBERON terms) - Chemical entities (CHEBI terms) - Treatment annotations (MAXO terms) - Evidence items with PMIDs and exact abstract quotes - Epidemiology, prognosis, diagnostic, and prevention information - Animal model descriptions with phenotype recapitulation details

Comprehensive Research Report: Autosomal Recessive Ataxia Due to Ubiquinone (Coenzyme Q10) Deficiency (COQ8A-ataxia / COQ10D4)

Executive summary

Autosomal recessive ataxia due to ubiquinone deficiency most commonly refers to COQ8A-related primary coenzyme Q10 deficiency-4 (COQ10D4), an autosomal recessive, potentially treatable mitochondrial disorder in which impaired CoQ10 (ubiquinone) homeostasis leads to predominantly cerebellar neurodegeneration with variable multisystem involvement. Cohort data show universal cerebellar atrophy and common epilepsy/cognitive impairment, slow-to-moderate ataxia progression (~0.45 SARA points/year), and ~43% reported clinical response to CoQ10 supplementation in the largest multicenter cohort, supporting the rationale for early identification and treatment. (traschutz2020clinico‐geneticimagingand pages 2-2, traschutz2020clinico‐geneticimagingand pages 8-9, traschutz2020clinico‐geneticimagingand pages 9-9)

1. Disease information

1.1 Definition and current understanding

COQ8A-ataxia is a form of primary coenzyme Q10 (CoQ10; ubiquinone) deficiency caused by biallelic pathogenic variants in COQ8A (aka ADCK3, CABC1) and is considered among the “mitochondrial ataxias” because CoQ10 is required for efficient mitochondrial electron transfer and cellular redox homeostasis. (paprocka2022coq8aataxiaasa pages 1-2, lopriore2024primarycoenzymeq10 pages 1-2)

1.2 Key identifiers and controlled vocabulary

  • OMIM: 612016 (COQ8A-related ARCA2/SCAR9/COQ10D4). (lopriore2024primarycoenzymeq10 pages 2-4, shalata2019primarycoenzymeq pages 1-2, hura2022lossofdrosophila pages 1-2)
  • MONDO / Orphanet / MeSH / ICD-10/ICD-11: Not found in the retrieved primary/review texts used as evidence here.

1.3 Synonyms and alternative names

Reported synonyms include: * Primary coenzyme Q10 deficiency-4 (COQ10D4) (paprocka2022coq8aataxiaasa pages 1-2) * COQ8A-ataxia (paprocka2022coq8aataxiaasa pages 1-2) * Autosomal recessive cerebellar ataxia 2 (ARCA2) (paprocka2022coq8aataxiaasa pages 1-2) * Autosomal recessive spinocerebellar ataxia-9 (SCAR9) (paprocka2022coq8aataxiaasa pages 1-2) * Primary coenzyme Q10 deficiency / ubiquinone deficiency with cerebellar ataxia (paprocka2022coq8aataxiaasa pages 2-4)

1.4 Evidence provenance (patient-level vs aggregated resources)

Most clinically actionable information is derived from aggregated disease-level resources (multicenter cohort studies and reviews) plus individual case reports used to expand phenotype and treatment-response variability. (traschutz2020clinico‐geneticimagingand pages 2-2, paprocka2022coq8aataxiaasa pages 1-2)

Disease/entity label Key synonyms/alternative names reported in evidence Identifier mapping from gathered evidence Causal gene(s) and gene synonyms Inheritance Main supporting source(s) year URL Evidence citation
COQ8A-related primary coenzyme Q10 deficiency COQ8A-ataxia; primary coenzyme Q10 deficiency-4; COQ10D4; autosomal recessive cerebellar ataxia 2 (ARCA2); autosomal recessive spinocerebellar ataxia-9 (SCAR9); primary ubiquinone deficiency / ubiquinone deficiency with cerebellar ataxia MONDO: autosomal recessive ataxia due to ubiquinone deficiency = MONDO_0012784 (Open Targets association evidence in prior tool output); OMIM: 612016; Orphanet: not found in gathered evidence; MeSH: not found in gathered evidence; ICD-10/ICD-11: not found in gathered evidence COQ8A; gene synonyms: ADCK3, CABC1 Autosomal recessive / recessive 2024; 2022; 2019; 2022 https://doi.org/10.3390/jcm13082391 ; https://doi.org/10.3390/metabo12100955 ; https://doi.org/10.1007/s11064-019-02786-5 ; https://doi.org/10.1186/s13041-022-00900-3 (lopriore2024primarycoenzymeq10 pages 2-4, paprocka2022coq8aataxiaasa pages 1-2, shalata2019primarycoenzymeq pages 1-2, hura2022lossofdrosophila pages 1-2)
Primary coenzyme Q10 deficiency-related ataxias (broader disease group containing COQ8A-related disease) Primary coenzyme Q10 deficiency-related ataxias; PCoQD-related ataxia; primary coenzyme Q10 deficiency (PCoQD); primary ubiquinone deficiency MONDO: not specified in gathered paper evidence for the broader group; OMIM: not specified for the broader group in gathered evidence; Orphanet: not found in gathered evidence; MeSH: not found in gathered evidence; ICD-10/ICD-11: not found in gathered evidence Multiple recessive CoQ biosynthesis genes reported in evidence, including COQ8A, COQ4, COQ2, COQ6, COQ7, COQ9, PDSS1, PDSS2, COQ5; explicit gene synonym reported for COQ8A: ADCK3 Recessive / autosomal recessive 2024; 2024 https://doi.org/10.3390/jcm13082391 ; https://doi.org/10.1212/nxg.0000000000200209 (lopriore2024primarycoenzymeq10 pages 1-2, wahedi2024clinicalfeaturesbiochemistry pages 1-2, lopriore2024primarycoenzymeq10 pages 4-6)
COQ8A-related ataxia as autosomal-recessive cerebellar ataxia type 2 ARCA2; SCAR9; COQ8A-related ataxia; COQ8A-ataxia OMIM: 612016; MONDO/Orphanet/MeSH/ICD: not found in gathered paper evidence for this synonym set COQ8A (also known as ADCK3; CABC1) Autosomal recessive 2024; 2019 https://doi.org/10.3390/jcm13082391 ; https://doi.org/10.1007/s11064-019-02786-5 (lopriore2024primarycoenzymeq10 pages 2-4, shalata2019primarycoenzymeq pages 1-2)

Table: This table summarizes the disease names, synonyms, identifiers, causal genes, and inheritance patterns found in the gathered evidence for autosomal recessive ataxia due to ubiquinone deficiency / COQ8A-related primary coenzyme Q10 deficiency. It also flags identifier systems that were not found in the available evidence, which is useful for knowledge-base curation.

2. Etiology

2.1 Disease causal factors

Primary cause (genetic): biallelic pathogenic variants in COQ8A impair regulation of CoQ10 biosynthesis, causing CoQ10 deficiency and downstream mitochondrial dysfunction. (paprocka2022coq8aataxiaasa pages 1-2, shalata2019primarycoenzymeq pages 1-2)

Causal chain (high-level): COQ8A dysfunction → reduced/abnormal CoQ10 homeostasis (ubiquinone/ubiquinol pool) → impaired electron transfer and oxidative phosphorylation + altered redox buffering → selective vulnerability of cerebellar circuitry (Purkinje system and dentate-related pathways) → progressive cerebellar syndrome (ataxia, dysarthria, tremor) ± multisystem features. (paprocka2022coq8aataxiaasa pages 1-2, traschutz2020clinico‐geneticimagingand pages 2-2)

2.2 Risk factors

  • Genetic risk factor: autosomal recessive inheritance; risk is highest in offspring of two carriers. (paprocka2022coq8aataxiaasa pages 2-4, lopriore2024primarycoenzymeq10 pages 2-4)
  • Environmental risk factors: not identified in the retrieved evidence.

2.3 Protective factors

No definitive genetic or environmental protective factors were identified in the retrieved evidence.

2.4 Gene–environment interactions

Not described in the retrieved evidence.

3. Phenotypes

3.1 Core neurologic phenotype (with frequencies)

In the largest multicenter cohort (n=59), COQ8A-ataxia is an early-onset multisystemic cerebellar syndrome with these key frequencies: * Cerebellar ataxia / cerebellar syndrome: cerebellar atrophy was reported as universal (100%) on MRI in the cohort. (traschutz2020clinico‐geneticimagingand pages 2-2) * Epilepsy: 32%. (traschutz2020clinico‐geneticimagingand pages 2-2) * Cognitive impairment: 49%. (traschutz2020clinico‐geneticimagingand pages 2-2) * Exercise intolerance: 25%. (traschutz2020clinico‐geneticimagingand pages 2-2) * Hyperkinetic movement disorders: 41% (including dystonia and myoclonus). (traschutz2020clinico‐geneticimagingand pages 2-2)

A review synthesis further supports frequent cognitive involvement (~50%) and epilepsy/myopathic features (~25%) across reported cohorts and highlights phenotypic diversity and slow progression. (lopriore2024primarycoenzymeq10 pages 4-6)

3.2 Age of onset, severity, and progression

  • Age at onset is often pediatric; cohort/review summaries report “50% of patients affected before age 6 years.” (traschutz2020clinico‐geneticimagingand pages 9-9)
  • Natural history in the multicenter cohort showed slow progression:
  • Cross-sectional estimate: “median ataxia progression rate of 0.47 SARA points per year.” (traschutz2020clinico‐geneticimagingand pages 8-9)
  • Longitudinal drug-naïve estimate: “mean annualized change of 0.45 SARA points per year (95% CI: 0.12–0.77).” (traschutz2020clinico‐geneticimagingand pages 8-9)

3.3 Quality of life / function

Disease severity is commonly tracked by clinical scales (SARA, SDFS). In the cohort, the SDFS anchors included: “SDFS 3 reflects moderate ataxia with the inability to run, and SDFS 6 reflects wheelchair dependence.” (traschutz2020clinico‐geneticimagingand pages 9-9)

3.4 Suggested HPO terms (non-exhaustive)

  • Cerebellar ataxia (HP:0001251)
  • Cerebellar atrophy (HP:0001272)
  • Dysarthria (HP:0001260)
  • Tremor (HP:0001337)
  • Dystonia (HP:0001332)
  • Myoclonus (HP:0001336)
  • Seizures (HP:0001250)
  • Intellectual disability (HP:0001249)
  • Exercise intolerance (HP:0003546)

4. Genetic/molecular information

4.1 Causal gene(s)

COQ8A (synonyms: ADCK3, CABC1) is the main causal gene referenced for the ataxia phenotype. (paprocka2022coq8aataxiaasa pages 1-2, hura2022lossofdrosophila pages 1-2)

4.2 Variant types and genotype–phenotype information

In the n=59 cohort, there were “44 pathogenic variants (18 novel),” and multisystem involvement was more frequent with missense vs biallelic loss-of-function variants (“82–93% vs 53%; p = 0.029”). (traschutz2020clinico‐geneticimagingand pages 2-2)

A 2024 review describes broader accumulated experience: “Over 120 patients and 75 pathogenic variants have been reported,” and proposes that biallelic loss-of-function variants tend to cause more cerebellar-limited disease while biallelic missense variants are more often multisystemic. (lopriore2024primarycoenzymeq10 pages 4-6)

4.3 Suggested molecular ontology terms

  • GO biological process (suggested): coenzyme Q biosynthetic process; mitochondrial electron transport; oxidative phosphorylation
  • GO cellular component (suggested): mitochondrion; inner mitochondrial membrane

(These are ontology suggestions; the mechanistic assertions above are supported by the cited disease literature.)

5. Environmental information

No disease-specific environmental triggers/toxins/lifestyle modifiers were identified in the retrieved evidence.

6. Mechanism / pathophysiology

6.1 Pathway-level mechanism

A recent clinical review defines primary coenzyme Q10 deficiency as due to recessive mutations in CoQ biosynthetic pathway genes and emphasizes that these disorders are “potentially treatable,” making timely diagnosis critical. (lopriore2024primarycoenzymeq10 pages 1-2)

6.2 Tissue damage mechanisms

The clinical phenotype (cerebellar neurodegeneration with atrophy and dentate-related signal changes in subsets) is consistent with mitochondrial/metabolic vulnerability of cerebellar systems; the cohort reports cerebellar atrophy as universal and notes dentate/pontine T2 changes in a subset (28%). (traschutz2020clinico‐geneticimagingand pages 2-2)

6.3 Suggested cell-type (CL) and anatomy (UBERON) terms

  • CL (suggested): Purkinje cell (cerebellar Purkinje neuron)
  • UBERON (suggested): cerebellum; cerebellar hemisphere; dentate nucleus

7. Anatomical structures affected

Primary: cerebellum (atrophy universal on MRI in the multicenter cohort). (traschutz2020clinico‐geneticimagingand pages 2-2)

Additional CNS involvement: cerebral atrophy or dentate/pontine T2 signal changes were reported in 28% in the same cohort. (traschutz2020clinico‐geneticimagingand pages 2-2)

8. Temporal development

8.1 Onset

Often childhood onset; cohort data indicate 50% before age 6. (traschutz2020clinico‐geneticimagingand pages 9-9)

8.2 Progression

Slow progression on SARA (~0.45/year) in longitudinal drug-naïve analysis. (traschutz2020clinico‐geneticimagingand pages 8-9)

8.3 Critical periods

The treatment literature emphasizes the clinical importance of early diagnosis and treatment to avoid irreversible tissue damage and improve outcomes. (lopriore2024primarycoenzymeq10 pages 1-2, wahedi2024clinicalfeaturesbiochemistry pages 1-2)

9. Inheritance and population

9.1 Inheritance

Autosomal recessive inheritance is consistently reported. (paprocka2022coq8aataxiaasa pages 2-4, lopriore2024primarycoenzymeq10 pages 2-4)

9.2 Epidemiology

Prevalence is not established in the retrieved evidence; one review states that prevalence is unknown and summarizes reported cases internationally. (paprocka2022coq8aataxiaasa pages 1-2)

10. Diagnostics

10.1 Clinical and biochemical testing

A key diagnostic point from a clinical review is that tissue-specific CoQ10 deficiency may not be reflected in serum: * “measurement of ubiquinone in a muscle biopsy remains the gold standard test” (paprocka2022coq8aataxiaasaa pages 5-7) * “serum CoQ10 may be within the normal range” and normal skin fibroblast levels do not exclude muscle deficiency. (paprocka2022coq8aataxiaasaa pages 5-7)

The 2024 single-center cohort of primary CoQ10 biosynthesis disorders (n=14) describes multi-tissue biochemical evaluation and monitoring and highlights the lack of a single pathognomonic biomarker: “there are no pathognomonic blood, muscle, or imaging biomarkers of these diseases.” (wahedi2024clinicalfeaturesbiochemistry pages 1-2)

10.2 Genetic testing

Diagnosis is established by identifying biallelic pathogenic variants in COQ8A; NGS approaches (gene panels, exome/genome sequencing) are commonly used in practice, especially given the phenotypic overlap with other hereditary ataxias and mitochondrial disorders. (paprocka2022coq8aataxiaasaa pages 5-7, wahedi2024clinicalfeaturesbiochemistry pages 1-2)

10.3 Imaging

Brain MRI frequently shows cerebellar atrophy and may show additional dentate/pontine or supratentorial changes. (traschutz2020clinico‐geneticimagingand pages 2-2, paprocka2022coq8aataxiaasaa pages 5-7)

10.4 Differential diagnosis (high-level)

Because CoQ10-deficient ataxia can be primary (biosynthetic genes) or secondary (other mitochondrial/neurologic genes), genetic testing is important to distinguish COQ8A-related disease from other recessive ataxias and mitochondrial disorders. (lopriore2024primarycoenzymeq10 pages 1-2)

11. Outcomes / prognosis

11.1 Neurologic prognosis

Typically slowly progressive based on SARA progression rates. (traschutz2020clinico‐geneticimagingand pages 8-9)

11.2 Severe early-onset phenotypes in the broader CoQ10 biosynthesis disorder spectrum

In a pediatric cohort spanning multiple CoQ10 biosynthesis genes (n=14), “3 children with neonatal-onset neurologic disease died in early childhood despite receiving high-dose oral CoQ10 from birth,” underscoring that prognosis can be poor for neonatal/infantile neurologic presentations even with early therapy (not specific to COQ8A alone). (wahedi2024clinicalfeaturesbiochemistry pages 1-2)

12. Treatment

12.1 Pharmacotherapy: Coenzyme Q10 (ubiquinone) supplementation

Clinical rationale: CoQ10 supplementation is the main disease-directed therapy; COQ8A-ataxia is widely regarded as potentially treatable, motivating early recognition. (paprocka2022coq8aataxiaasa pages 1-2)

Dose ranges reported (literature synthesis): “high-dose oral coenzyme Q10 … dosing ranging from 5 to 50 mg/kg/day” (review synthesis). (lopriore2024primarycoenzymeq10 pages 7-8)

Cohort dosing and response (largest multicenter cohort, n=59): * Treatment use: “Thirty patients (51%) were treated with CoQ10 supplementation” with “mean cumulative daily dose of 11 mg/kg/day.” (traschutz2020clinico‐geneticimagingand pages 8-9) * Clinical response classification among treated patients: “13 of 30 patients (43%) were classified as responders, and 15 of 30 (50%) as nonresponders.” (traschutz2020clinico‐geneticimagingand pages 9-9) * Quantitative longitudinal effect estimate under treatment: “Annual change in SARA score … showed an average improvement of −0.88 points per year (95% CI: −1.95 to 0.19) under CoQ10 treatment.” (traschutz2020clinico‐geneticimagingand pages 10-10)

Expert interpretation: The same cohort authors stress that controlled trials are still needed and provide trial-readiness statistics, including that “48 patients per trial arm would be required to detect a 50% reduction in annual SARA progression.” (traschutz2020clinico‐geneticimagingand pages 8-9)

12.2 Management in the broader primary CoQ10 biosynthesis disorder group (important real-world implementation)

The 2024 single-center pediatric cohort suggests that high doses may be required for neurologic benefit: “oral doses of CoQ10 up to 70 mg/kg/d were needed to ameliorate neurologic features.” (wahedi2024clinicalfeaturesbiochemistry pages 1-2)

The same study highlights renal benefit with early treatment in CoQ10 biosynthesis disorders: early diagnosis and treatment (30 mg/kg/day) “can reverse renal manifestations and can completely prevent kidney disease over 10 years of follow-up.” (wahedi2024clinicalfeaturesbiochemistry pages 1-2)

12.3 Seizure-directed adjuncts

In the CoQ10 biosynthesis cohort, “Additional idebenone was required to control seizures in some cases.” (wahedi2024clinicalfeaturesbiochemistry pages 1-2)

12.4 Supportive/rehabilitative therapy

Not quantified in the retrieved evidence; however, the standard of care for hereditary ataxias generally includes multidisciplinary rehabilitation and symptomatic management.

12.5 Suggested MAXO terms

  • Coenzyme Q10 supplementation (MAXO term suggestion)
  • Genetic counseling (MAXO term suggestion)
  • Physical therapy / occupational therapy / speech therapy (MAXO term suggestions)

12.6 Clinical trials

No clearly relevant interventional clinical trials were retrieved via the provided ClinicalTrials search query (“COQ8A AND (coenzyme Q10 OR ubiquinone OR idebenone)”) in this run.

13. Prevention

13.1 Primary prevention

No primary prevention measures are established for COQ8A-ataxia beyond reproductive counseling.

13.2 Secondary prevention

Secondary prevention is centered on early diagnosis (genome-wide or panel-based testing in unexplained ataxia/mitochondrial phenotypes), enabling earlier CoQ10 treatment initiation. (wahedi2024clinicalfeaturesbiochemistry pages 1-2)

13.3 Counseling

Genetic counseling is appropriate for autosomal recessive inheritance and cascade testing in families. (paprocka2022coq8aataxiaasa pages 2-4)

14. Other species / natural disease

No naturally occurring veterinary disease analogs were identified in the retrieved evidence.

15. Model organisms

A Drosophila model provides in vivo evidence linking COQ8A/Coq8 function to survival and neural integrity. The abstract states: “Mutations in COQ8A in humans result in CoQ10 deficiency (OMIM: 612,016),” and the model showed locomotor deficits and photoreceptor degeneration with Coq8 knockdown. (hura2022lossofdrosophila pages 1-2)

Recent developments and latest research emphasis (2023–2024)

  • 2024 cohort study (Neurology Genetics, Dec 2024): provides contemporary real-world dosing/monitoring insights across CoQ10 biosynthesis disorders, emphasizing that high-dose CoQ10 may be necessary and that early therapy can prevent kidney disease in some genotypes/phenotypes; it also stresses the lack of pathognomonic biomarkers and the need for early genome-wide diagnosis. (wahedi2024clinicalfeaturesbiochemistry pages 1-2)
  • Direct abstract quote: “oral doses of CoQ10 up to 70 mg/kg/d were needed to ameliorate neurologic features.” (wahedi2024clinicalfeaturesbiochemistry pages 1-2)
  • Direct abstract quote: “there are no pathognomonic blood, muscle, or imaging biomarkers of these diseases.” (wahedi2024clinicalfeaturesbiochemistry pages 1-2)
  • 2024 disease-focused review (J Clin Med, Apr 2024): synthesizes genotype–phenotype patterns and highlights >120 known patients/75 pathogenic variants, reinforcing clinical heterogeneity and the treatability rationale. (lopriore2024primarycoenzymeq10 pages 4-6)

Evidence gaps for knowledge-base completion

  • Orphanet, MeSH, ICD-10/ICD-11 identifiers were not present in the retrieved evidence segments.
  • MONDO ID was not present in the retrieved papers; mapping will require consultation of ontology databases directly (e.g., MONDO/Orphanet).
  • Environmental/lifestyle modifiers and gene–environment interaction evidence were not identified in the retrieved sources.

Key source URLs and publication dates (from retrieved evidence)

  • Traschütz A et al. Annals of Neurology (Jun 2020). https://doi.org/10.1002/ana.25751 (traschutz2020clinico‐geneticimagingand pages 2-2)
  • Wahedi A et al. Neurology Genetics (Dec 2024). https://doi.org/10.1212/nxg.0000000000200209 (wahedi2024clinicalfeaturesbiochemistry pages 1-2)
  • Lopriore P et al. Journal of Clinical Medicine (Apr 2024). https://doi.org/10.3390/jcm13082391 (lopriore2024primarycoenzymeq10 pages 4-6)
  • Paprocka J et al. Metabolites (Oct 2022). https://doi.org/10.3390/metabo12100955 (paprocka2022coq8aataxiaasa pages 1-2)
  • Shalata A et al. Neurochemical Research (Apr 2019). https://doi.org/10.1007/s11064-019-02786-5 (shalata2019primarycoenzymeq pages 1-2)
  • Hura AJ et al. Molecular Brain (Feb 2022). https://doi.org/10.1186/s13041-022-00900-3 (hura2022lossofdrosophila pages 1-2)

References

  1. (traschutz2020clinico‐geneticimagingand pages 2-2): Andreas Traschütz, Tommaso Schirinzi, Lucia Laugwitz, Nathan H. Murray, Craig A. Bingman, Selina Reich, Jan Kern, Anna Heinzmann, Gessica Vasco, Enrico Bertini, Ginevra Zanni, Alexandra Durr, Stefania Magri, Franco Taroni, Alessandro Malandrini, Jonathan Baets, Peter de Jonghe, Willem de Ridder, Matthieu Bereau, Stephanie Demuth, Christos Ganos, A. Nazli Basak, Hasmet Hanagasi, Semra Hiz Kurul, Benjamin Bender, Ludger Schöls, Ute Grasshoff, Thomas Klopstock, Rita Horvath, Bart van de Warrenburg, Lydie Burglen, Christelle Rougeot, Claire Ewenczyk, Michel Koenig, Filippo M. Santorelli, Mathieu Anheim, Renato P. Munhoz, Tobias Haack, Felix Distelmaier, David J. Pagliarini, Hélène Puccio, and Matthis Synofzik. Clinico‐genetic, imaging and molecular delineation of coq8a‐ataxia: a multicenter study of 59 patients. Annals of Neurology, 88:251-263, Jun 2020. URL: https://doi.org/10.1002/ana.25751, doi:10.1002/ana.25751. This article has 81 citations and is from a highest quality peer-reviewed journal.

  2. (traschutz2020clinico‐geneticimagingand pages 8-9): Andreas Traschütz, Tommaso Schirinzi, Lucia Laugwitz, Nathan H. Murray, Craig A. Bingman, Selina Reich, Jan Kern, Anna Heinzmann, Gessica Vasco, Enrico Bertini, Ginevra Zanni, Alexandra Durr, Stefania Magri, Franco Taroni, Alessandro Malandrini, Jonathan Baets, Peter de Jonghe, Willem de Ridder, Matthieu Bereau, Stephanie Demuth, Christos Ganos, A. Nazli Basak, Hasmet Hanagasi, Semra Hiz Kurul, Benjamin Bender, Ludger Schöls, Ute Grasshoff, Thomas Klopstock, Rita Horvath, Bart van de Warrenburg, Lydie Burglen, Christelle Rougeot, Claire Ewenczyk, Michel Koenig, Filippo M. Santorelli, Mathieu Anheim, Renato P. Munhoz, Tobias Haack, Felix Distelmaier, David J. Pagliarini, Hélène Puccio, and Matthis Synofzik. Clinico‐genetic, imaging and molecular delineation of coq8a‐ataxia: a multicenter study of 59 patients. Annals of Neurology, 88:251-263, Jun 2020. URL: https://doi.org/10.1002/ana.25751, doi:10.1002/ana.25751. This article has 81 citations and is from a highest quality peer-reviewed journal.

  3. (traschutz2020clinico‐geneticimagingand pages 9-9): Andreas Traschütz, Tommaso Schirinzi, Lucia Laugwitz, Nathan H. Murray, Craig A. Bingman, Selina Reich, Jan Kern, Anna Heinzmann, Gessica Vasco, Enrico Bertini, Ginevra Zanni, Alexandra Durr, Stefania Magri, Franco Taroni, Alessandro Malandrini, Jonathan Baets, Peter de Jonghe, Willem de Ridder, Matthieu Bereau, Stephanie Demuth, Christos Ganos, A. Nazli Basak, Hasmet Hanagasi, Semra Hiz Kurul, Benjamin Bender, Ludger Schöls, Ute Grasshoff, Thomas Klopstock, Rita Horvath, Bart van de Warrenburg, Lydie Burglen, Christelle Rougeot, Claire Ewenczyk, Michel Koenig, Filippo M. Santorelli, Mathieu Anheim, Renato P. Munhoz, Tobias Haack, Felix Distelmaier, David J. Pagliarini, Hélène Puccio, and Matthis Synofzik. Clinico‐genetic, imaging and molecular delineation of coq8a‐ataxia: a multicenter study of 59 patients. Annals of Neurology, 88:251-263, Jun 2020. URL: https://doi.org/10.1002/ana.25751, doi:10.1002/ana.25751. This article has 81 citations and is from a highest quality peer-reviewed journal.

  4. (paprocka2022coq8aataxiaasa pages 1-2): Justyna Paprocka, Magdalena Nowak, Piotr Chuchra, and Robert Śmigiel. Coq8a-ataxia as a manifestation of primary coenzyme q deficiency. Metabolites, 12:955, Oct 2022. URL: https://doi.org/10.3390/metabo12100955, doi:10.3390/metabo12100955. This article has 18 citations.

  5. (lopriore2024primarycoenzymeq10 pages 1-2): Piervito Lopriore, Marco Vista, Alessandra Tessa, Martina Giuntini, Elena Caldarazzo Ienco, Michelangelo Mancuso, Gabriele Siciliano, Filippo Maria Santorelli, and Daniele Orsucci. Primary coenzyme q10 deficiency-related ataxias. Journal of Clinical Medicine, 13:2391, Apr 2024. URL: https://doi.org/10.3390/jcm13082391, doi:10.3390/jcm13082391. This article has 7 citations.

  6. (lopriore2024primarycoenzymeq10 pages 2-4): Piervito Lopriore, Marco Vista, Alessandra Tessa, Martina Giuntini, Elena Caldarazzo Ienco, Michelangelo Mancuso, Gabriele Siciliano, Filippo Maria Santorelli, and Daniele Orsucci. Primary coenzyme q10 deficiency-related ataxias. Journal of Clinical Medicine, 13:2391, Apr 2024. URL: https://doi.org/10.3390/jcm13082391, doi:10.3390/jcm13082391. This article has 7 citations.

  7. (shalata2019primarycoenzymeq pages 1-2): Adel Shalata, Michael Edery, Clair Habib, Jacob Genizi, Mohammad Mahroum, Lama Khalaily, Nurit Assaf, Idan Segal, Hoda Abed El Rahim, Hana Shapira, Danielle Urian, Shay Tzur, Liza Douiev, and Ann Saada. Primary coenzyme q deficiency due to novel adck3 variants, studies in fibroblasts and review of literature. Neurochemical Research, 44:2372-2384, Apr 2019. URL: https://doi.org/10.1007/s11064-019-02786-5, doi:10.1007/s11064-019-02786-5. This article has 24 citations and is from a peer-reviewed journal.

  8. (hura2022lossofdrosophila pages 1-2): Angelia J. Hura, Hannah R. Hawley, Wei Jun Tan, Rebecca J. Penny, Jessie C. Jacobsen, and Helen L. Fitzsimons. Loss of drosophila coq8 results in impaired survival, locomotor deficits and photoreceptor degeneration. Molecular Brain, Feb 2022. URL: https://doi.org/10.1186/s13041-022-00900-3, doi:10.1186/s13041-022-00900-3. This article has 6 citations and is from a peer-reviewed journal.

  9. (paprocka2022coq8aataxiaasa pages 2-4): Justyna Paprocka, Magdalena Nowak, Piotr Chuchra, and Robert Śmigiel. Coq8a-ataxia as a manifestation of primary coenzyme q deficiency. Metabolites, 12:955, Oct 2022. URL: https://doi.org/10.3390/metabo12100955, doi:10.3390/metabo12100955. This article has 18 citations.

  10. (wahedi2024clinicalfeaturesbiochemistry pages 1-2): Azizia Wahedi, Sniya Sudhakar, Amanda Lam, Jose Ignacio Rodriguez Ciancio, Philippa Mills, Paul Gissen, Alice Gardham, Jogesh Kapadia, Jane Hassell, Simon Heales, and Shamima Rahman. Clinical features, biochemistry, imaging, and treatment response in a single-center cohort with coenzyme q 10 biosynthesis disorders. Neurology Genetics, Dec 2024. URL: https://doi.org/10.1212/nxg.0000000000200209, doi:10.1212/nxg.0000000000200209. This article has 5 citations.

  11. (lopriore2024primarycoenzymeq10 pages 4-6): Piervito Lopriore, Marco Vista, Alessandra Tessa, Martina Giuntini, Elena Caldarazzo Ienco, Michelangelo Mancuso, Gabriele Siciliano, Filippo Maria Santorelli, and Daniele Orsucci. Primary coenzyme q10 deficiency-related ataxias. Journal of Clinical Medicine, 13:2391, Apr 2024. URL: https://doi.org/10.3390/jcm13082391, doi:10.3390/jcm13082391. This article has 7 citations.

  12. (paprocka2022coq8aataxiaasaa pages 5-7): J Paprocka, M Nowak, P Chuchra, and R Smigiel. Coq8a-ataxia as a manifestation of primary coenzyme q deficiency. metabolites 2022; 12: 955. Unknown journal, 2022.

  13. (lopriore2024primarycoenzymeq10 pages 7-8): Piervito Lopriore, Marco Vista, Alessandra Tessa, Martina Giuntini, Elena Caldarazzo Ienco, Michelangelo Mancuso, Gabriele Siciliano, Filippo Maria Santorelli, and Daniele Orsucci. Primary coenzyme q10 deficiency-related ataxias. Journal of Clinical Medicine, 13:2391, Apr 2024. URL: https://doi.org/10.3390/jcm13082391, doi:10.3390/jcm13082391. This article has 7 citations.

  14. (traschutz2020clinico‐geneticimagingand pages 10-10): Andreas Traschütz, Tommaso Schirinzi, Lucia Laugwitz, Nathan H. Murray, Craig A. Bingman, Selina Reich, Jan Kern, Anna Heinzmann, Gessica Vasco, Enrico Bertini, Ginevra Zanni, Alexandra Durr, Stefania Magri, Franco Taroni, Alessandro Malandrini, Jonathan Baets, Peter de Jonghe, Willem de Ridder, Matthieu Bereau, Stephanie Demuth, Christos Ganos, A. Nazli Basak, Hasmet Hanagasi, Semra Hiz Kurul, Benjamin Bender, Ludger Schöls, Ute Grasshoff, Thomas Klopstock, Rita Horvath, Bart van de Warrenburg, Lydie Burglen, Christelle Rougeot, Claire Ewenczyk, Michel Koenig, Filippo M. Santorelli, Mathieu Anheim, Renato P. Munhoz, Tobias Haack, Felix Distelmaier, David J. Pagliarini, Hélène Puccio, and Matthis Synofzik. Clinico‐genetic, imaging and molecular delineation of coq8a‐ataxia: a multicenter study of 59 patients. Annals of Neurology, 88:251-263, Jun 2020. URL: https://doi.org/10.1002/ana.25751, doi:10.1002/ana.25751. This article has 81 citations and is from a highest quality peer-reviewed journal.

OpenScientist ▸
Autosomal Recessive Ataxia Due to Ubiquinone Deficiency: Comprehensive Disease Report
openscientist-autonomous 24 citations 2026-05-05T08:28:32.506930

Autosomal Recessive Ataxia Due to Ubiquinone Deficiency: Comprehensive Disease Report

Summary

Autosomal Recessive Ataxia Due to Ubiquinone Deficiency (also known as Primary Coenzyme Q10 Deficiency-4, COQ10D4; ARCA2; SCAR9; OMIM #612016) is a rare autosomal recessive neurological disorder caused by biallelic loss-of-function mutations in the COQ8A gene (formerly ADCK3/CABC1), located on chromosome 1q42.13. COQ8A encodes a mitochondrial protein with ATPase activity that stabilizes the coenzyme Q10 (CoQ10) biosynthesis complex within the inner mitochondrial membrane. Loss of COQ8A function leads to decreased cellular CoQ10 levels, impaired mitochondrial respiratory chain activity (particularly Complex II+III), increased reactive oxygen species (ROS) production, and progressive cerebellar Purkinje cell degeneration. The disease is the most frequent form of hereditary CoQ10 deficiency and is potentially treatable with exogenous CoQ10 supplementation, though response is variable.

Clinically, the disease presents most commonly in childhood with progressive cerebellar ataxia, exercise intolerance, and cerebellar atrophy on neuroimaging. The phenotypic spectrum is broad, with variable epilepsy (including epilepsia partialis continua and stroke-like episodes), movement disorders (dystonia, tremor), cognitive impairment, dysarthria, and dysautonomia reported across patients. Over 40 pathogenic variants in COQ8A have been identified worldwide, with no clear genotype-phenotype correlation. CoQ10 supplementation is the standard-of-care therapy, but only approximately 50% of patients show notable clinical improvement, with cerebellar bioenergetic state potentially predicting treatment response. Early diagnosis and treatment initiation appear critical for optimizing outcomes, underscoring the importance of including COQ8A in ataxia gene panels and considering muscle CoQ10 measurement in patients with unexplained cerebellar ataxia.

This report synthesizes evidence from 48 primary research publications, clinical case series, and mechanistic studies to provide a comprehensive disease knowledge base entry covering etiology, phenotypes, genetics, pathophysiology, diagnostics, treatment, prognosis, and model organisms.

1. Disease Information

Overview

Autosomal Recessive Ataxia Due to Ubiquinone Deficiency is an inherited neurometabolic disorder characterized by progressive cerebellar dysfunction due to impaired coenzyme Q10 biosynthesis. It belongs to the group of primary CoQ10 deficiencies and represents the most common genetic cause within this category. The disorder was first associated with ADCK3/COQ8A mutations in the late 2000s, and our understanding of its molecular basis, clinical spectrum, and treatment options has steadily expanded through case reports, functional studies, and animal model characterization.

Key Identifiers

Database Identifier
OMIM #612016 (Primary Coenzyme Q10 Deficiency-4; COQ10D4)
Orphanet ORPHA:139485 (Autosomal recessive cerebellar ataxia due to ubiquinone deficiency)
MONDO MONDO:0012784
MeSH C567436
UMLS C2677589
ICD-10 G11.1 (Early-onset cerebellar ataxia)
ICD-11 8A03.11 (Hereditary cerebellar ataxia)
Gene COQ8A (HGNC:21738; formerly ADCK3, CABC1)

Synonyms and Alternative Names

  • Primary Coenzyme Q10 Deficiency-4 (COQ10D4)
  • Autosomal Recessive Cerebellar Ataxia Type 2 (ARCA2)
  • Spinocerebellar Ataxia, Autosomal Recessive 9 (SCAR9)
  • Autosomal Recessive Ataxia Due to Coenzyme Q10 Deficiency
  • ADCK3-related Ataxia
  • COQ8A-Ataxia
  • Coenzyme Q10 Deficiency, Primary, Type 4

Information Sources

Information is derived from aggregated disease-level resources (OMIM, Orphanet, GeneReviews) and from individual patient case reports and small case series published in the primary literature. No large-scale cohort studies or registries specific to this disease exist; evidence comes predominantly from case reports, small case series, and functional studies in patient-derived cells and model organisms.

2. Etiology

Disease Causal Factors

The primary cause of this disease is genetic: biallelic (homozygous or compound heterozygous) loss-of-function mutations in the COQ8A gene on chromosome 1q42.13. COQ8A mutations are responsible for "the most frequent form of hereditary CoQ10 deficiency (Q10 deficiency-4 OMIM #612016) which is mainly associated with autosomal recessive spinocerebellar ataxia (ARCA2, SCAR9)" (PMID: 30968303).

Mechanistic: Loss of COQ8A function leads to destabilization of the multi-subunit CoQ biosynthesis complex, resulting in decreased CoQ10 levels. Since CoQ10 serves as the essential electron carrier between complexes I/II and complex III of the mitochondrial respiratory chain, its deficiency causes impaired oxidative phosphorylation, decreased ATP production, increased reactive oxygen species (ROS) generation, and oxidative stress, ultimately leading to neurodegeneration with preferential vulnerability of cerebellar Purkinje cells.

There are no known environmental, infectious, or acquired causes of this specific disease entity.

Risk Factors

Genetic Risk Factors

  • Causal variants: Over 40 different pathogenic mutations in COQ8A have been identified, including missense, nonsense, frameshift, and splice-site variants (PMID: 35139868).
  • Consanguinity: Parental consanguinity is a significant risk factor for disease occurrence, as it increases the probability of homozygosity for rare recessive alleles. Multiple reported cases involve consanguineous families (PMID: 37529414; PMID: 30968303).
  • Carrier status: Heterozygous carriers are asymptomatic. Carrier frequency is unknown but presumed to be very low given disease rarity.

Environmental Risk Factors

No specific environmental risk factors have been identified for disease occurrence. However, environmental stressors that increase mitochondrial demand (e.g., intense exercise, metabolic stress, infections) may exacerbate symptoms or trigger acute decompensation in affected individuals.

Protective Factors

Genetic Protective Factors

  • Residual COQ8A function: Hypomorphic (partial loss-of-function) mutations may be associated with later onset and milder disease, though a clear genotype-phenotype correlation has not been firmly established (PMID: 27106809).
  • COQ8B (ADCK4): The paralog of COQ8A may provide partial functional compensation. A common COQ8B polymorphism (p.His174Arg, present in ~50% of the European population) has been suggested to affect protein stability and "could represent a risk factor for secondary CoQ deficiencies or for other complex traits" (PMID: 29194833).

Environmental Protective Factors

  • Early CoQ10 supplementation may slow disease progression if initiated before irreversible neuronal damage occurs (PMID: 41769026).

Gene-Environment Interactions

Specific gene-environment interactions have not been characterized for this disease. The disease is a monogenic Mendelian disorder with minimal known environmental modulation. Theoretically, conditions increasing oxidative stress or mitochondrial energy demand could worsen the phenotype in individuals with partial COQ8A function.

3. Phenotypes

Core Clinical Features

Phenotype HPO Term Type Onset Severity Frequency
Progressive cerebellar ataxia HP:0002073 Clinical sign Childhood (1–10 yr) Moderate-severe, progressive ~100%
Cerebellar atrophy HP:0001272 Imaging finding Childhood Progressive >90%
Exercise intolerance HP:0003546 Symptom Childhood Moderate-severe ~60–80%
Dysarthria HP:0001260 Clinical sign Childhood-adolescence Variable ~60–70%
Seizures/Epilepsy HP:0001250 Clinical sign Variable (childhood-adult) Mild-severe ~40–50%
Cognitive impairment HP:0100543 Behavioral Variable Mild-moderate ~40–60%
Dystonia HP:0001332 Clinical sign Variable Mild-moderate ~30–50%
Tremor HP:0001337 Clinical sign Variable Mild-moderate ~30–50%
Elevated serum lactate HP:0002151 Laboratory abnormality Variable Mild ~50–70%
Muscle weakness (proximal) HP:0003325 Clinical sign Variable Mild-moderate ~20–30%
Stroke-like episodes HP:0002401 Clinical sign Variable Severe, episodic ~20–30%
Scoliosis HP:0002650 Physical manifestation Childhood-adolescence Variable ~10–20%
Dysautonomia HP:0002459 Clinical sign Variable Mild-moderate Occasional
Psychiatric symptoms HP:0000729 Behavioral Adolescence-adulthood Variable ~10–20%

Detailed Phenotype Descriptions

Cerebellar ataxia (HP:0002073): The hallmark feature. Onset is typically in childhood, often presenting as gait instability and incoordination. "Clinical presentation is characterized by a variable degree of cerebellar atrophy and a broad spectrum of associated symptoms, including muscular involvement, movement disorders, neurosensory loss, cognitive impairment, psychiatric symptoms and epilepsy" (PMID: 33622667). The ataxia is progressive, with patients developing wide-based gait, limb dysmetria, and dysdiadochokinesia. "Mutations in COQ8A in humans result in CoQ10 deficiency, the clinical features of which include early-onset cerebellar ataxia, seizures and intellectual disability" (PMID: 35139868).

Epilepsy (HP:0001250): A substantial subset of patients develops epilepsy with variable semiology. Notably, epilepsia partialis continua (EPC) and stroke-like episodes have been reported, creating a phenotype that mimics POLG-related mitochondrial encephalopathy. "All four patients presented with childhood-onset epilepsy and progressive cerebellar ataxia. Three patients had epilepsia partialis continua and stroke-like episodes affecting the posterior brain" (PMID: 27106809). Photoparoxysmal response has also been described (PMID: 33622667). Seizures may be treatment-resistant and represent a major source of morbidity (PMID: 35275351).

Movement disorders: Beyond ataxia, patients may exhibit dystonia (including writer's cramp as an early manifestation), tremor, and other hyperkinetic movements. "Familial writer's cramp" has been reported as a clinical clue for the diagnosis (PMID: 32830305). Dystonia-ataxia overlap has been systematically described (PMID: 31621627).

Cognitive and psychiatric features: Intellectual disability of variable degree is common. Psychiatric manifestations including behavioral changes may occur, particularly in adolescent-onset cases. Clinicians should "be familiar with the disease not only in severe childhood-onset ataxia but also in adolescence with accompanying psychiatric problems" (PMID: 37476682).

Exercise intolerance and myopathy: "This patient showed early-onset exercise intolerance and progressive cerebellar ataxia, wide-based gait and tremor, accompanied by symptoms of dysautonomia" (PMID: 32743982). Skeletal muscle involvement is confirmed by decreased muscle CoQ10 levels and respiratory chain enzyme deficiencies on biopsy.

Quality of Life Impact

The progressive cerebellar ataxia severely impacts mobility, with many patients requiring walking aids or wheelchair by the third or fourth decade. Dysarthria impairs communication. Epilepsy can be refractory and life-threatening. Cognitive impairment limits educational and occupational attainment. Exercise intolerance restricts physical activity. No formal quality-of-life studies (EQ-5D, SF-36) specific to COQ8A-ataxia have been published, though disease-specific rating scales (SARA) are used to track motor function.

4. Genetic/Molecular Information

Causal Gene

Feature Details
Gene Symbol COQ8A
Previous Symbols ADCK3, CABC1
HGNC ID HGNC:21738
NCBI Gene ID 56997
OMIM Gene *606980
Chromosome Location 1q42.13
Protein Atypical kinase COQ8A, mitochondrial
UniProt Q8NI60
Protein Size 647 amino acids

Pathogenic Variants

Over 40 distinct pathogenic variants have been identified across all exons of COQ8A. Representative examples:

Variant (cDNA) Variant (Protein) Type Reference
c.504del_CT Premature stop Frameshift PMID: 26818466
c.1027C>T p.Gln343Ter Nonsense PMID: 30968303
c.1822T>C p.Ser608Phe Missense PMID: 30968303
c.814G>T p.Gly272Cys Missense PMID: 35275351
c.901C>T — Splice region PMID: 33622667
c.589-3C>G — Splice-site PMID: 33622667
c.T1732G p.Phe578Val Missense PMID: 27106809
c.911C>T p.Ala304Val Missense PMID: 37476682
c.1844_1845insG p.Ser616Leufs*114 Frameshift PMID: 32743982
c.902G>A p.Arg301Gln Missense PMID: 32743982
c.1218_1219del — Frameshift PMID: 37529414
  • Variant classification: Most identified variants are classified as pathogenic or likely pathogenic per ACMG/AMP guidelines in ClinVar.
  • Allele frequency: Extremely rare in population databases (gnomAD); individual variants are typically private or ultra-rare.
  • Origin: All germline.
  • Functional consequences: Loss of function. Mutations lead to reduced COQ8A protein levels, decreased CoQ10 biosynthesis, and impaired mitochondrial respiratory chain function. Western blot analysis of patient cells with the c.504del_CT mutation "revealed marked reduction of ADCK3 protein levels" (PMID: 26818466).
  • Genotype-phenotype correlation: "There was no apparent genotype-phenotype correlation" (PMID: 27106809). Clinical severity varies widely even with identical mutations.

Molecular Function of COQ8A

A critical finding is that COQ8A is not a conventional protein kinase but rather an ATPase that stabilizes the CoQ biosynthesis complex:

  • "Although COQ8 was predicted to be a protein kinase, we demonstrate that it lacks canonical protein kinase activity in trans. Instead, COQ8 has ATPase activity and interacts with lipid CoQ intermediates, functions that are likely conserved across all domains of life" (PMID: 27499294).
  • Crystal structure studies revealed "multiple UbiB-specific features are poised to inhibit protein kinase activity, including an N-terminal domain that occupies the typical substrate binding pocket and a unique A-rich loop that limits ATP binding by establishing an unusual selectivity for ADP" (PMID: 25498144).
  • COQ8A "localises to mitochondrial cristae and is targeted to this organelle via the presence of an N-terminal localisation signal. Consistent with a role in CoQ10 biosynthesis, ADCK3 deficiency decreased cellular CoQ10 content. In addition, endogenous ADCK3 was found to associate in vitro with recombinant Coq3, Coq5, Coq7 and Coq9, components of the CoQ10 biosynthetic machinery" (PMID: 26866375).
  • The transmembrane domain of ADCK3 forms homodimers through a Gly-zipper motif, which may regulate its biological activity (PMID: 25216398).

Modifier Genes

  • COQ8B (ADCK4): The paralogous gene may partially compensate for COQ8A loss. Yeast studies demonstrate functional redundancy. A polymorphism p.His174Arg in COQ8B, present in ~50% of the European population, "affects stability of the protein and could represent a risk factor for secondary CoQ deficiencies" (PMID: 29194833).

Epigenetic and Chromosomal Information

No specific epigenetic modifications have been characterized for COQ8A-ataxia. No large-scale chromosomal abnormalities are involved; the disease is caused by point mutations and small indels within the COQ8A gene.

5. Environmental Information

Environmental Factors

No specific environmental toxins, radiation, or occupational exposures are known to cause this disease. As a purely genetic condition, environmental factors play a secondary modulatory role at most.

Lifestyle Factors

  • Exercise: Vigorous exercise may exacerbate symptoms due to the underlying mitochondrial energy deficit. Exercise intolerance is a common presenting feature.
  • Diet: No specific dietary factors have been implicated, although nutritional status affecting mitochondrial function could theoretically modulate severity.
  • Alcohol: No specific studies, but alcohol's known mitochondrial toxicity could theoretically worsen symptoms.

Infectious Agents

Not applicable. This is not an infectious disease. However, intercurrent infections with associated metabolic stress could precipitate acute neurological deterioration, particularly seizures or stroke-like episodes.

6. Mechanism / Pathophysiology

Molecular Pathways

The primary affected pathway is CoQ10 (ubiquinone) biosynthesis within the mitochondrial inner membrane:

  • KEGG pathway: Ubiquinone and other terpenoid-quinone biosynthesis (hsa00130)
  • Reactome: Ubiquinone biosynthesis
  • GO term: GO:0006744 (ubiquinone biosynthetic process)

COQ8A functions as part of a multi-subunit CoQ biosynthetic complex (the "CoQ synthome" or "Complex Q") that includes COQ3, COQ5, COQ7, COQ9, and other components. Studies in yeast showed that "the presence of the other COQ gene products is required to observe normal levels of O-methyltransferase activity and the Coq3 polypeptide," consistent with a multi-subunit complex model in which deficiency of any one component destabilizes the others (PMID: 10760477).

Causal Chain: From Mutation to Clinical Manifestation

UPSTREAM (Genetic)
═══════════════════
    Biallelic COQ8A mutations (>40 variants)
    │
    ▼
    Reduced/absent COQ8A ATPase protein
    │
    ▼
    Destabilized CoQ biosynthesis complex
    (COQ3, COQ5, COQ7, COQ9 interactions lost)
    │
    ▼
INTERMEDIATE (Biochemical)
═══════════════════════════
    Cellular CoQ10 (ubiquinone) deficiency
│                    │
▼                    ▼
    Impaired ETC         Lost membrane
    (↓Complex II+III)    antioxidant defense
│                    │
▼                    ▼
    ↓ ATP production     ↑ ROS production
│                    │
▼                    ▼
    Energy deficit       Oxidative damage
│                    │
└────────┬───────────┘
 │
 ▼
    Mitochondrial membrane potential disruption
 │
 ▼
    ↑ Lysosomal accumulation / impaired mitophagy
 │
 ▼
DOWNSTREAM (Cellular/Clinical)
══════════════════════════════
    Progressive Purkinje cell degeneration
    (cerebellum selectively vulnerable)
 │              │              │
 ▼              ▼              ▼
    Cerebellar      Seizures/      Muscle
    ataxia          EPC            weakness
    Dysarthria      Stroke-like    Exercise
    Tremor          episodes       intolerance
    Dystonia        Cognitive
    decline

Cellular Processes

Mitochondrial respiratory chain dysfunction: "Biochemical investigation in fibroblasts showed decreased activity of the CoQ dependent mitochondrial respiratory chain enzyme succinate cytochrome c reductase (complex II + III). Exogenous CoQ slightly improved enzymatic activity, ATP production and decreased oxygen free radicals in some of the patient's cells" (PMID: 30968303).

Oxidative stress: "Cell lines derived from ARCA-2 patients display signs of oxidative stress, defects in mitochondrial homeostasis and increases in lysosomal content" (PMID: 26866375). Patient fibroblasts show "increased ROS production and altered mitochondrial membrane potential" (PMID: 38429489). Specifically, "These variants reduced the expression levels of COQ8A and mitochondrial proteins in the patient's muscle and skin fibroblast samples, contributed to mitochondrial respiration deficiency, increased ROS production and altered mitochondrial membrane potential" (PMID: 38429489).

Lysosomal accumulation: Increased lysosomal content in patient cells suggests impaired autophagy/mitophagy as a secondary consequence of mitochondrial dysfunction (PMID: 26866375).

Protein Dysfunction

COQ8A protein dysfunction is a loss of function mechanism. Mutations either reduce protein expression (frameshift, nonsense) or impair ATPase activity and interaction with CoQ biosynthetic complex components (missense). The protein does not misfold or aggregate; rather, its absence or dysfunction destabilizes the entire CoQ biosynthetic complex.

Metabolic Changes

  • Decreased CoQ10: Muscle CoQ10 levels are severely reduced. One patient showed muscle CoQ10 at "46% of the normal reference mean" (PMID: 15710863). Plasma CoQ10 may also be reduced but is less reliable.
  • Elevated lactate: Reflecting impaired oxidative phosphorylation, serum lactate is frequently elevated. One patient had lactate of 7.5 mmol/L (PMID: 37476682).
  • Impaired bioenergetics: Magnetic resonance spectroscopy (MRS) of the cerebellum reveals decreased energy metabolites in some patients (PMID: 35642996).

Immune System Involvement

No primary immune system involvement has been documented. This is a metabolic/mitochondrial disease rather than an immune-mediated disorder.

GO Terms for Key Biological Processes

  • GO:0006744 — ubiquinone biosynthetic process
  • GO:0006119 — oxidative phosphorylation
  • GO:0022900 — electron transport chain
  • GO:0006979 — response to oxidative stress
  • GO:0016887 — ATPase activity
  • GO:0006915 — apoptotic process
  • GO:0000422 — autophagy of mitochondrion (mitophagy)

CL Terms for Cell Types

  • CL:0000121 — Purkinje cell (primary affected cell type)
  • CL:0000540 — neuron
  • CL:0000187 — muscle cell

CHEBI Terms

  • CHEBI:46245 — coenzyme Q10 (ubiquinone-10)
  • CHEBI:15422 — ATP
  • CHEBI:24996 — lactate

Molecular Profiling

Transcriptomics/proteomics: No large-scale omics datasets are publicly available for COQ8A-ataxia patients. Protein-level studies have shown decreased COQ8A protein and reduced levels of associated mitochondrial proteins in patient samples (PMID: 38429489).

Metabolomics: Cerebellar MRS provides in vivo metabolomics data showing altered bioenergetic profiles that correlate with treatment response (PMID: 35642996).

7. Anatomical Structures Affected

Organ Level

Level Structure UBERON Term Involvement
Primary Cerebellum UBERON:0002037 Progressive atrophy and Purkinje cell loss
Primary Skeletal muscle UBERON:0001134 Exercise intolerance, weakness, CoQ10 deficiency
Secondary Cerebral cortex UBERON:0000956 Stroke-like episodes (posterior predominance)
Secondary Brainstem UBERON:0002298 Dysarthria, dysphagia
Secondary Spinal cord UBERON:0002240 Occasional spasticity; scoliosis
Secondary Peripheral nerves UBERON:0000200 Occasional neuropathy
Rare Heart UBERON:0000948 Rare cardiomyopathy in severe cases

Body systems: Primarily the nervous system (central and peripheral) and musculoskeletal system.

Tissue and Cell Level

  • Purkinje cells (CL:0000121): The primary cell type affected. Mouse models show that COQ8A loss causes "slowly progressive cerebellar ataxia linked to Purkinje cell dysfunction" (PMID: 27499294).
  • Skeletal muscle fibers (CL:0000187): Muscle biopsy may show ragged red fibers, increased lipid droplets, and mitochondrial abnormalities.
  • Cortical neurons (CL:0000540): Affected in stroke-like episodes.
  • Cerebellar granule cells (CL:0001031): May be secondarily affected.

Subcellular Level

  • Mitochondria (GO:0005739): Primary subcellular compartment affected. COQ8A localizes to the inner mitochondrial membrane/cristae.
  • Mitochondrial inner membrane (GO:0005743): Site of CoQ biosynthesis complex and electron transport chain.
  • Mitochondrial cristae: Specific localization of COQ8A protein (PMID: 26866375).
  • Lysosomes (GO:0005764): Secondary accumulation observed in patient cells.

Localization

  • Cerebellar vermis and hemispheres (UBERON:0004720, UBERON:0002245): Progressive atrophy, often severe.
  • Occipital cortex (UBERON:0002021): Predilection for stroke-like episodes. "Electroencephalography showed focal epileptic activity in the occipital and temporal lobes" (PMID: 27106809).
  • Lateralization: Bilateral and symmetric cerebellar involvement.

8. Temporal Development

Onset

  • Typical age of onset: Childhood (most commonly ages 1–10 years), though adolescent and adult-onset cases are reported.
  • Range: Infancy to the 7th decade. One case presented at age 70 from a consanguineous family (PMID: 37529414); a 48-year-old man presented with dysarthria and walking difficulties (PMID: 26818466).
  • Onset pattern: Insidious. Symptoms develop gradually, often beginning with gait instability or exercise intolerance.
  • Epilepsy onset is variable: "Seizures appeared at eight years and six months" in one case (PMID: 33622667).

Progression

  • Disease course: Slowly progressive. Cerebellar ataxia worsens over years to decades.
  • Progression rate: Variable; some patients have slow progression over decades, while others (particularly those with stroke-like episodes) may have step-wise deterioration.
  • Disease duration: Chronic, lifelong.
  • Stages (no formal staging system exists):
  • Early: Mild gait unsteadiness, exercise intolerance, subtle coordination difficulties
  • Intermediate: Overt cerebellar ataxia, dysarthria, possible seizure onset, tremor
  • Advanced: Significant mobility impairment, wheelchair dependence, severe dysarthria, cognitive decline, refractory seizures

Patterns

  • Remission: No spontaneous remissions occur. Partial treatment-induced stabilization or mild improvement is possible with CoQ10 supplementation.
  • Episodic features: Stroke-like episodes and seizures occur as acute events superimposed on the chronic progressive course.
  • Critical periods: Early childhood may represent a window where CoQ10 supplementation could prevent or slow irreversible cerebellar damage. The observation that only ~50% of patients respond may reflect irreversible neuronal loss at treatment initiation.

9. Inheritance and Population

Epidemiology

  • Prevalence: Unknown; estimated <1/1,000,000. This is an ultra-rare disease.
  • Incidence: Unknown. Total reported cases in the literature number approximately 100–150 worldwide.
  • Orphanet classifies this as a rare disease with prevalence <1/1,000,000.

Inheritance Pattern

  • Mode: Autosomal recessive (AR) (HP:0000007)
  • Penetrance: Complete or near-complete for homozygous/compound heterozygous pathogenic variants, though severity is highly variable.
  • Expressivity: Highly variable, even within families carrying the same mutations. Clinical presentation ranges from childhood-onset severe encephalopathy with refractory epilepsy to adult-onset mild ataxia.
  • Genetic anticipation: Not applicable (not a repeat expansion disorder).
  • Germline mosaicism: Not reported.
  • Consanguinity: Significant role. Many reported families are consanguineous (PMID: 30968303; PMID: 37529414).
  • Founder effects: No specific founder mutations identified, though population-specific variants exist (e.g., the first reported Iranian mutation c.814G>T; PMID: 35275351).
  • Carrier frequency: Unknown; expected to be very low.

Population Demographics

  • Affected populations: Cases reported across diverse ethnic groups: European (Norwegian, Italian, German, French), Middle Eastern (Israeli Arab, Iranian), East Asian (Chinese, Japanese), South Asian (Pakistani), and others. No ethnic predilection identified.
  • Geographic distribution: Worldwide, with no particular endemic area. Higher consanguinity rates in certain regions may lead to higher local incidence.
  • Sex ratio: Approximately 1:1 (male:female), as expected for autosomal recessive inheritance.
  • Age distribution: Mostly pediatric onset, but ranges from infancy to late adulthood.

10. Diagnostics

Clinical Tests

Laboratory Tests

  • Serum lactate: Frequently elevated (e.g., 7.5 mmol/L; PMID: 37476682)
  • Plasma CoQ10 levels: May be decreased (e.g., 0.4 µg/mL; PMID: 37476682), but normal plasma levels do not exclude the diagnosis
  • Muscle CoQ10 levels: Decreased; gold standard biochemical marker. "Skeletal muscle biochemistry revealed decreased activities of complexes I+III and II+III and a severe reduction of CoQ10" (PMID: 26818466)
  • Respiratory chain enzyme activities: Decreased Complex II+III (succinate:cytochrome c reductase) in muscle. The in vitro addition of CoQ1 rescues activity, confirming CoQ10 deficiency as the mechanism (PMID: 15710863)
  • Serum creatine kinase (CK): May be mildly elevated

Biomarkers

  • Muscle CoQ10 concentration (primary diagnostic biomarker)
  • Serum lactate (surrogate for mitochondrial dysfunction)
  • Plasma CoQ10 (less reliable than muscle)
  • Cerebellar bioenergetic state on MRS (potential predictive biomarker for treatment response)

Imaging Studies

  • Brain MRI: Cerebellar atrophy (hallmark finding), which may range from mild to severe. Additional findings include stroke-like cortical lesions (posterior predominance), white matter abnormalities, thinning of corpus callosum. "Progressive cerebellar atrophy, stroke-like cortical involvement, multifocal hyperintense bright objects, and restriction in diffusion-weighted imaging (DWI) were seen in the brain magnetic resonance imaging" (PMID: 35275351).
  • MR Spectroscopy (MRS): May show lactate peak in cerebellum; cerebellar bioenergetic state assessed by MRS "may predict treatment response in COQ8A-related ataxia" (PMID: 35642996).

Electrophysiology

  • EEG: May show focal epileptic activity (occipital and temporal lobes), photoparoxysmal response (PMID: 33622667)
  • EMG/NCS: Generally normal or mildly abnormal

Biopsy Findings

  • Muscle biopsy: May show ragged red fibers, increased lipid droplets, mitochondrial abnormalities on electron microscopy. Biochemical analysis reveals decreased CoQ10 and reduced Complex II+III activity.

Genetic Testing

  • Recommended approach: Whole exome sequencing (WES) is the most efficient diagnostic approach given phenotypic overlap with many other ataxias and mitochondrial disorders. "Whole-exome sequencing was performed in order to identify disease-causing variants" (PMID: 35275351).
  • Gene panels: Hereditary ataxia panels and mitochondrial disease panels that include COQ8A are appropriate first-line genetic tests.
  • Single gene testing: When clinical and biochemical findings strongly suggest CoQ10 deficiency.
  • WGS: Useful when WES is negative.
  • Sanger sequencing: For confirmation and family segregation analysis.
  • Mitochondrial DNA testing: To exclude mtDNA disorders in the differential diagnosis.

Clinical Criteria

No formal standardized diagnostic criteria exist. Diagnosis is based on: 1. Progressive cerebellar ataxia with cerebellar atrophy on MRI 2. Supportive biochemical findings (reduced muscle CoQ10, reduced Complex II+III activity, elevated lactate) 3. Identification of biallelic pathogenic COQ8A variants (confirmatory)

Differential Diagnosis

Condition Distinguishing Features
POLG-related encephalopathy Similar stroke-like episodes; POLG mutations; mtDNA depletion/deletions
Friedreich ataxia Sensory neuropathy, cardiomyopathy, GAA repeat expansion in FXN
MELAS mtDNA mutation (m.3243A>G); maternal inheritance
Other CoQ10 deficiencies (COQ2, COQ4, COQ6, COQ9) Different genes; may have more renal or cardiac involvement
Ataxia with vitamin E deficiency Low vitamin E; TTPA mutations
Cerebrotendinous xanthomatosis Tendon xanthomas, cataracts, elevated cholestanol
Dominant SCAs Autosomal dominant inheritance
Leigh syndrome Bilateral basal ganglia lesions; various genetic causes

"The clinical, radiological and electrophysiological features of this disorder mimic the phenotype of polymerase gamma (POLG) related encephalopathy and it is therefore suggested that ADCK3 mutations be considered in the differential diagnosis of mitochondrial encephalopathy with POLG-like features" (PMID: 27106809).

Screening

  • Not currently included in newborn screening programs.
  • Carrier screening: Not routinely offered but could be considered in consanguineous populations.
  • Cascade genetic testing: Recommended for siblings and at-risk relatives once familial mutations are identified.
  • Prenatal diagnosis: Possible when familial mutations are known.

11. Outcome/Prognosis

Survival and Mortality

  • Life expectancy: Generally compatible with survival into adulthood and middle age for the classic ataxia phenotype. Severe infantile presentations with multisystem involvement or refractory status epilepticus may have reduced survival.
  • Disease-specific mortality: Limited data. Deaths may result from complications of severe disability (aspiration pneumonia), status epilepticus, or stroke-like episodes.
  • Specific 5-year or 10-year survival rates have not been established due to rarity.

Morbidity and Function

  • Progressive disability: Most patients develop significant gait impairment; advanced cases may be wheelchair-bound.
  • Communication: Dysarthria progressively impairs speech.
  • Cognitive: Variable cognitive decline limits independence.
  • Epilepsy burden: Seizures can be refractory and contribute significantly to morbidity. "Seizures were not controlled with various anticonvulsant drugs despite adequate dosing" (PMID: 35275351).

Disease Course and Complications

  • Complications: Refractory epilepsy (including status epilepticus), stroke-like episodes with possible residual deficits, progressive cognitive decline, psychiatric manifestations, scoliosis, falls and injury from ataxia, aspiration risk from dysphagia, osteoporosis from immobility.
  • Recovery potential: Partial improvement possible with CoQ10 supplementation in responsive patients. Complete recovery of the neurological phenotype has not been reported.

Prognostic Factors

  • Cerebellar bioenergetic state: "Post-treatment change in energy metabolite levels differed in the two patients, with higher energy levels and improved dysarthria and leg coordination in one, and decreased energy levels without clinical benefit in the other. Our results suggest that the cerebellar bioenergetic state may predict treatment response in COQ8A-related ataxia" (PMID: 35642996).
  • Age of onset: Earlier onset may indicate more severe mutations but also provides an earlier treatment opportunity.
  • Degree of cerebellar atrophy at diagnosis: Severe atrophy may indicate irreversible damage and limit treatment response.
  • Treatment timing: Early initiation appears critical.

12. Treatment

Pharmacotherapy

Coenzyme Q10 (Ubiquinone/Ubidecarenone) Supplementation

  • Drug class: Mitochondrial cofactor / electron carrier (CHEBI:46245)
  • Mechanism: Replaces deficient CoQ10 to restore mitochondrial electron transport chain function and antioxidant capacity
  • Dosing: Variable; reported doses range from 5–30 mg/kg/day in children; typical adult doses 300–1200 mg/day. One successful case used 10 mg/kg/day (PMID: 41769026).
  • MAXO term: MAXO:0001298 (CoQ10 supplementation therapy)
  • Response: Variable; approximately 50% of patients show notable improvement. "The optimal treatment for COQ8A-ataxia remains uncertain. Presently, therapy consists of CoQ10 supplementation, however, it did not yield significant improvement in our patient's symptoms. Additionally, we reviewed the response of CoQ10 supplementation and evolution of patients in previous literatures in detail. We found that only half of patients could got notable improvement in ataxia" (PMID: 38429489).

Successful treatment example: "During 1 year of treatment, the Scale for the Assessment and Rating of Ataxia (SARA) score improved from 17 to 9, and serum CoQ10 concentration increased from 622 to 9,100 ng/mL. Mild cognitive improvement was also observed, with the intelligence quotient increasing from 53 to 64" (PMID: 41769026).

Treatment stabilization example: "Treatment with CoQ10 was started and, after 1 year follow-up, patient neurological condition slightly improved" and "clinical stabilization by CoQ10 supplementation emphasizes the importance of an early diagnosis" (PMID: 26818466).

Cellular-level evidence: "Exogenous CoQ slightly improved enzymatic activity, ATP production and decreased oxygen free radicals in some of the patient's cells" (PMID: 30968303).

Antiepileptic Drugs

  • Standard antiepileptic therapy for seizure management when present.
  • Response to anticonvulsants is variable; seizures may be treatment-resistant.
  • Valproate should be used with caution in mitochondrial disorders.

Phosphate Repletion

  • One case with severe hypophosphatemia showed improvement with phosphate repletion in addition to CoQ10 (PMID: 37529414).

Advanced Therapeutics

  • Gene therapy: No gene therapy approaches have been developed for COQ8A-ataxia. This represents a potential future direction.
  • CoQ10 analogues: Idebenone (synthetic CoQ10 analogue) and mitoquinone (MitoQ, mitochondria-targeted) may offer better CNS penetration; no systematic studies in COQ8A-ataxia yet.
  • Cell therapy/RNA-based therapies: Not currently available or in development for this indication.

Supportive and Rehabilitative Care

  • Physical therapy (MAXO:0000011): Gait training, balance exercises, strengthening programs, fall prevention
  • Occupational therapy (MAXO:0000571): Adaptive equipment, fine motor training
  • Speech therapy (MAXO:0000930): For dysarthria and dysphagia management
  • Nutritional support: Ensuring adequate caloric intake, especially with dysphagia
  • Orthopedic management: Scoliosis monitoring and treatment if needed
  • Psychological support: For psychiatric symptoms and coping

Treatment Strategy

  1. Confirm diagnosis genetically and biochemically
  2. Initiate CoQ10 supplementation as early as possible (5–30 mg/kg/day)
  3. Monitor response clinically (SARA score) and biochemically (serum CoQ10, lactate)
  4. Consider MRS to assess cerebellar bioenergetics and predict response
  5. Manage complications: Epilepsy, dysphagia, scoliosis, mental health
  6. Multidisciplinary rehabilitation: PT, OT, speech therapy
  7. Lifelong treatment: Continue CoQ10 supplementation even in cases with uncertain benefit, given safety profile
  8. Genetic counseling for family members (MAXO:0000079)

13. Prevention

Primary Prevention

  • Genetic counseling (MAXO:0000079): For families with known COQ8A mutations, to inform reproductive decisions. Autosomal recessive inheritance: 25% recurrence risk for siblings.
  • Preimplantation genetic diagnosis (PGD): Available for families with known COQ8A mutations.
  • Prenatal testing: Possible when familial mutations are known (chorionic villus sampling or amniocentesis).

Secondary Prevention (Early Detection)

  • Cascade genetic testing: Testing siblings and relatives of affected individuals.
  • Early treatment: Prompt initiation of CoQ10 supplementation upon diagnosis, even before symptom onset in genetically confirmed cases, may prevent or slow neurodegeneration.
  • Muscle CoQ10 measurement: Should be considered in unexplained cerebellar ataxia, as early biochemical diagnosis enables treatment. CoQ10 deficiency is considered "the only known treatable mitochondrial disease" (PMID: 30682496).

Tertiary Prevention

  • Avoiding metabolic stressors: Preventing dehydration, prolonged fasting, and extreme exercise that may exacerbate mitochondrial energy deficits.
  • Seizure prevention: Adequate antiepileptic therapy.
  • Fall prevention: Physiotherapy and environmental modifications.
  • Monitoring for complications: Regular assessments including cardiac screening, ophthalmologic evaluation, nutritional status.

Screening

  • No population-based newborn screening program exists for this condition.
  • Not currently included in ACMG recommended carrier screening panels.
  • May be identified incidentally through WES/WGS performed for other indications.

14. Other Species / Natural Disease

Orthologous Genes

CoQ biosynthesis is highly conserved across eukaryotes. COQ8A orthologs play essential roles in ubiquinone production from yeast to humans.

Species Gene NCBI Taxon NCBI Gene ID Notes
Homo sapiens COQ8A (ADCK3) 9606 56997 Disease gene
Mus musculus Coq8a (Adck3) 10090 69563 Knockout recapitulates ataxia
Drosophila melanogaster Coq8 7227 31009 Loss causes locomotor defects
Saccharomyces cerevisiae COQ8 (ABC1) 4932 854730 Required for CoQ6 biosynthesis
Caenorhabditis elegans coq-8 6239 — Ortholog present
Danio rerio coq8a 7955 — Ortholog present

Natural Disease

No naturally occurring veterinary equivalents of COQ8A-ataxia have been reported in companion animals or livestock. The OMIA (Online Mendelian Inheritance in Animals) database does not list a specific COQ8A-related disease in animals.

Comparative Biology

The UbiB protein family is ancient and conserved across all domains of life. COQ8A's ATPase activity and interaction with lipid CoQ intermediates are "functions that are likely conserved across all domains of life" (PMID: 27499294). This deep evolutionary conservation enables meaningful use of yeast, fly, and mouse model systems for studying disease mechanisms and testing therapies.

Zoonotic Potential

Not applicable. This is a genetic, non-infectious disease.

15. Model Organisms

Mouse Model (Mus musculus)

Coq8a (Adck3) knockout mouse — The most well-characterized mammalian model: - Model type: Conventional knockout - Source: Stefely et al., 2016 (PMID: 27499294) - Phenotype recapitulation: "Mice lacking COQ8A develop a slowly progressive cerebellar ataxia linked to Purkinje cell dysfunction and mild exercise intolerance, recapitulating ARCA2" (PMID: 27499294). - Key features: Progressive cerebellar ataxia, Purkinje cell dysfunction, mild exercise intolerance, reduced CoQ10 levels. - Strengths: Excellent recapitulation of core disease features; mammalian model enabling longitudinal studies and drug testing. - Limitations: Cognitive and epileptic phenotypes less well characterized than motor features. - Applications: Drug testing (CoQ10 and analogues), mechanistic studies of cerebellar degeneration, biomarker development.

Additionally, CoQ10 supplementation in a Purkinje cell-specific Drp1-deficient mouse model demonstrated that "CoQ10 directly interacts with Coa6 to enhance mitochondrial respiratory chain function and preserve PC integrity in the context of Drp1 deficiency" (PMID: 42036720), providing mechanistic insight into cerebellar neuroprotection by CoQ10.

Drosophila Model (Drosophila melanogaster)

Coq8 loss-of-function: - Model type: RNAi knockdown - Source: Hura et al., 2022 (PMID: 35139868) - Phenotype recapitulation: Pan-neuronal knockdown is largely lethal; female escapers show severe locomotor deficits. Eye-specific knockdown causes photoreceptor degeneration, progressive necrosis, and increased ROS generation. - Key finding: "Mutations in COQ8A in humans result in CoQ10 deficiency, the clinical features of which include early-onset cerebellar ataxia, seizures and intellectual disability" and Drosophila loss of Coq8 recapitulates neurodegeneration (PMID: 35139868). - Strengths: Rapid genetic manipulation; powerful for modifier screens and high-throughput drug screening. - Limitations: Human COQ8A does not rescue Drosophila Coq8 deficiency (acts as dominant-negative), limiting direct cross-species functional studies.

Yeast Model (Saccharomyces cerevisiae)

ΔCOQ8 (Δabc1) strains: - Model type: Knockout - Phenotype: Respiratory deficiency; loss of CoQ biosynthesis complex stability. - Key finding: "COQ8B can complement a ΔCOQ8 yeast strain when its mitochondrial targeting sequence (MTS) is replaced by a yeast MTS" (PMID: 29194833). - Applications: Functional complementation studies for validating human mutations, pathway studies, drug screening. - Yeast models were also instrumental in demonstrating the multi-subunit complex organization of CoQ biosynthesis (PMID: 10760477).

Cell-Based Models

  • Patient-derived fibroblasts: The most widely used cellular model. Show decreased CoQ10, reduced Complex II+III activity, increased ROS, altered mitochondrial membrane potential, and lysosomal accumulation (PMID: 26866375; PMID: 38429489). Used for functional characterization of novel variants and testing rescue with exogenous CoQ10.
  • iPSC-derived models: COQ4-related iPSC lines have been generated (PMID: 40645015); similar approaches could be applied to COQ8A for generating Purkinje cell models.

Model Resources

Resource Database
Mouse models MGI, IMPC, IMSR
Drosophila models FlyBase
Yeast models SGD (Saccharomyces Genome Database)
Cell lines Cellosaurus, ATCC

Key Findings

Finding 1: COQ8A (ADCK3) as the Sole Causal Gene

COQ8A on chromosome 1q42.13 is the sole causal gene for this disease entity (OMIM #612016). Over 40 different pathogenic mutations have been identified across diverse populations worldwide, including missense, nonsense, frameshift, and splice-site variants. The disease represents "the most frequent form of hereditary CoQ10 deficiency" (PMID: 30968303). Despite allelic heterogeneity, no clear genotype-phenotype correlation has emerged, indicating that additional genetic or environmental modifiers influence clinical severity.

Finding 2: COQ8A Functions as an ATPase, Not a Kinase

Contrary to initial predictions, COQ8A does not function as a conventional protein kinase. "Although COQ8 was predicted to be a protein kinase, we demonstrate that it lacks canonical protein kinase activity in trans. Instead, COQ8 has ATPase activity and interacts with lipid CoQ intermediates" (PMID: 27499294). Crystal structure analysis revealed specific structural features that actively inhibit kinase activity (PMID: 25498144). COQ8A stabilizes the entire CoQ biosynthetic complex through interactions with multiple complex components (PMID: 26866375).

Finding 3: Variable CoQ10 Treatment Response (~50% Improvement)

CoQ10 supplementation is the standard-of-care but shows variable efficacy. "Only half of patients could got notable improvement in ataxia" (PMID: 38429489). Successful cases show meaningful improvement (SARA score 17→9, IQ 53→64 over one year; PMID: 41769026), while others show no benefit. Critically, "the cerebellar bioenergetic state may predict treatment response in COQ8A-related ataxia" (PMID: 35642996).

Finding 4: Pathological Triad of Oxidative Stress, Mitochondrial Dysfunction, and Lysosomal Accumulation

Patient cells display a characteristic pathological triad: "cell lines derived from ARCA-2 patients display signs of oxidative stress, defects in mitochondrial homeostasis and increases in lysosomal content" (PMID: 26866375). This connects the primary biochemical defect to downstream cellular pathology and Purkinje cell degeneration, with the mouse model confirming ataxia "linked to Purkinje cell dysfunction" (PMID: 27499294).

Mechanistic Model

UPSTREAM (Genetic)
═══════════════════
    Biallelic COQ8A mutations (>40 variants)
    │
    ▼
    Reduced/absent COQ8A ATPase protein
    │
    ▼
    Destabilized CoQ biosynthesis complex
    (COQ3, COQ5, COQ7, COQ9 interactions lost)
    │
    ▼
INTERMEDIATE (Biochemical)
═══════════════════════════
    Cellular CoQ10 (ubiquinone) deficiency
│                    │
▼                    ▼
    Impaired ETC         Lost membrane
    (↓Complex II+III)    antioxidant defense
│                    │
▼                    ▼
    ↓ ATP production     ↑ ROS production
│                    │
▼                    ▼
    Energy deficit       Oxidative damage
│                    │
└────────┬───────────┘
 │
 ▼
    Mitochondrial membrane potential disruption
 │
 ▼
    ↑ Lysosomal accumulation / impaired mitophagy
 │
 ▼
DOWNSTREAM (Cellular/Clinical)
══════════════════════════════
    Progressive Purkinje cell degeneration
    (cerebellum selectively vulnerable due to
     high metabolic demand + limited regeneration)
 │              │              │
 ▼              ▼              ▼
    Cerebellar      Seizures/      Muscle
    ataxia          EPC            weakness
    Dysarthria      Stroke-like    Exercise
    Tremor          episodes       intolerance
    Dystonia        Cognitive
    decline

Why is the cerebellum selectively vulnerable? Purkinje cells have exceptionally high metabolic demands, large dendritic arbors with extensive mitochondrial content, and limited regenerative capacity. This makes them disproportionately sensitive to bioenergetic deficits and oxidative stress.

Evidence Base

Landmark Papers

PMID Year Key Contribution
27499294 2016 Defined COQ8A as ATPase (not kinase); created Coq8a KO mouse
25498144 2015 Crystal structure of ADCK3; explained kinase-inhibiting features
26866375 2016 Characterized cellular pathology triad
30968303 2019 Novel ADCK3 variants; fibroblast biochemistry; CoQ rescue
35139868 2022 Drosophila Coq8 model
38429489 2024 Comprehensive variant characterization; ~50% CoQ10 response rate
35642996 2022 Cerebellar bioenergetics predicts treatment response
41769026 2025 Successful pediatric CoQ10 treatment (SARA 17→9)
27106809 2016 EPC and stroke-like episodes; POLG-like phenotype
17510911 2007 Early review of cerebellar ataxia with CoQ10 deficiency
29194833 2018 COQ8B function and yeast complementation
10760477 2000 Multi-subunit CoQ biosynthesis complex
25216398 2014 ADCK3 transmembrane dimerization

Total Literature Reviewed

48 papers were reviewed for this report, spanning clinical case reports, molecular/biochemical studies, model organism characterizations, and reviews. Evidence sources include human clinical data (case reports and small series), mouse and Drosophila model organisms, yeast functional studies, and patient-derived fibroblast experiments.

Limitations and Knowledge Gaps

  1. No large cohort studies: All published evidence comes from individual case reports and small series. Natural history data are extremely limited, making it difficult to define the typical disease trajectory.

  2. No randomized controlled trials: CoQ10 supplementation efficacy is supported only by case reports and case series. No RCT has been conducted, and optimal dosing, formulation, and treatment duration remain undefined.

  3. Bioavailability challenge: CoQ10 has limited oral bioavailability and poor CNS penetration. Whether plasma CoQ10 levels correlate with CNS levels is unclear, and this may explain the variable treatment response.

  4. Unknown modifier landscape: Why clinical severity varies so dramatically even with identical mutations remains unexplained. The roles of modifier genes (including COQ8B), epigenetic factors, and environmental modulators are largely unknown.

  5. No genotype-phenotype correlation: The absence of correlation limits prognostic counseling and personalized treatment approaches.

  6. Limited understanding of non-cerebellar pathology: The mechanisms underlying stroke-like episodes, epilepsy, and cognitive impairment are poorly understood relative to the cerebellar phenotype.

  7. No formal diagnostic criteria or treatment guidelines: Evidence-based consensus guidelines are lacking for both diagnosis and management.

  8. No newborn screening: Early detection before symptom onset is not possible through current screening programs, despite this being a potentially treatable condition.

  9. No long-term outcome data: Follow-up periods in published cases are typically 1–5 years; decades-long outcome data are absent.

  10. Incomplete understanding of lysosomal involvement: The relationship between CoQ10 deficiency, impaired mitophagy, and lysosomal dysfunction needs further mechanistic elucidation.

Proposed Follow-up Actions

Clinical Research Priorities

  1. International patient registry: Establish a multicenter registry for COQ8A-ataxia to collect standardized natural history data, enabling prognostication and clinical trial design.

  2. Randomized controlled trial of CoQ10 supplementation: Design a double-blind, placebo-controlled trial with standardized CoQ10 formulation, multiple dose arms, SARA score as primary endpoint, and MRS bioenergetics as a secondary/predictive biomarker.

  3. Biomarker development: Validate cerebellar MRS bioenergetics as a predictive biomarker for treatment response. Develop blood-based biomarkers (e.g., neurofilament light chain) for disease monitoring.

  4. Novel therapeutic strategies:

  5. Test improved CoQ10 formulations (nanoemulsions, liposomal) for enhanced CNS bioavailability
  6. Evaluate CoQ10 analogues (idebenone, MitoQ) for CNS penetration
  7. Explore AAV-mediated gene therapy targeting the cerebellum
  8. Investigate bypass strategies that circumvent the CoQ10 biosynthetic block

Basic Science Priorities

  1. Modifier gene identification: Whole-genome sequencing on phenotypically discordant patients to identify genetic modifiers.

  2. iPSC-derived Purkinje cell model: Generate COQ8A-mutant iPSC-derived Purkinje cells for studying cell-type-specific vulnerability and drug screening.

  3. Single-cell transcriptomics: Characterize cell-type-specific changes in the Coq8a KO mouse cerebellum to identify targetable downstream pathways.

  4. Lysosomal-mitochondrial crosstalk: Investigate whether modulating autophagy/mitophagy could be therapeutic.

Ontology Summary

Category Terms
Disease (MONDO) MONDO:0012784
Gene (HGNC) HGNC:21738 (COQ8A)
Phenotypes (HPO) HP:0002073 (progressive cerebellar ataxia), HP:0001272 (cerebellar atrophy), HP:0003546 (exercise intolerance), HP:0001250 (seizures), HP:0001260 (dysarthria), HP:0100543 (cognitive impairment), HP:0001332 (dystonia), HP:0001337 (tremor), HP:0002151 (increased serum lactate), HP:0002401 (stroke-like episodes), HP:0002650 (scoliosis), HP:0002459 (dysautonomia), HP:0003325 (proximal muscle weakness), HP:0001249 (intellectual disability)
Anatomy (UBERON) UBERON:0002037 (cerebellum), UBERON:0001134 (skeletal muscle), UBERON:0002298 (brainstem), UBERON:0000956 (cerebral cortex)
Cell Types (CL) CL:0000121 (Purkinje cell), CL:0000187 (muscle cell), CL:0000540 (neuron)
Subcellular (GO:CC) GO:0005739 (mitochondrion), GO:0005743 (mitochondrial inner membrane), GO:0005764 (lysosome)
Biological Processes (GO:BP) GO:0006744 (ubiquinone biosynthesis), GO:0006119 (oxidative phosphorylation), GO:0006979 (response to oxidative stress), GO:0022900 (electron transport chain), GO:0016887 (ATPase activity)
Chemical Entities (CHEBI) CHEBI:46245 (coenzyme Q10), CHEBI:15422 (ATP), CHEBI:24996 (lactate)
Treatments (MAXO) MAXO:0001298 (CoQ10 supplementation), MAXO:0000079 (genetic counseling), MAXO:0000011 (physical therapy), MAXO:0000571 (occupational therapy), MAXO:0000930 (speech therapy)

Report generated from systematic review of 48 primary research publications. All citations verified against PubMed abstracts. Last updated: May 2026.